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ABSTRACT 
Recurrent episodes of airway obstruction, hypoxemia and pulmonary hypertension (PH) are present 
during exacerbations of severe equine asthma (SEA). Pulmonary hypoxic vasoconstriction is known 
to contribute to the development of PH, which may lead to cor pulmonale. However, as PH is only 
partially reversible by oxygen administration, other etiological factors are likely to be involved. In 
human chronic obstructive pulmonary disease, pulmonary artery (PA) remodeling contributes to the 
development of PH. Furthermore, allergic airway inflammation results in remodeling of pulmonary 
vasculature in mouse models, suggesting that similar findings may be present in asthma. We therefore 
postulated that PA remodeling is present in SEA and contributes to PH. The project aimed to 
investigate 1) the presence of PA remodeling in severe equine asthma and its distribution throughout 
the lungs, 2) the involvement of vascular smooth muscle (VSM) alterations, and 3) their reversibility 
following long-term antigen avoidance strategies or inhaled corticosteroids administration. Using 
histomorphometry and tissue bank (ERTB) lung samples, the PA wall was measured on sections 
stained with hematoxylin-eosin saffron, collected post-mortem from different lung regions of 12 
asthmatic horses and 6 age-matched controls. Pulmonary vascular smooth muscle (VSM) mass was 
also measured on sections stained for α-smooth muscle actin collected with in vivo thoracoscopy or 
post-mortem peripheral lung biopsy from 5 controls, 6 asthmatic horses in remission, and 11 
asthmatic horses while exacerbation and after 1 year of antigen avoidance alone (5 horses) or 
treatments with fluticasone (6 horses). Data were compared using one tailed unpaired t tests with 
Welch correction or paired t tests (p<0.05). Increased PA wall surface was detected in apical 
(p=0.002) and caudodorsal (p=0.03) lung regions of asthmatic horses in both exacerbation and 
remission, when compared to controls. The VSM mass was similarly increased (p=0.03) when 
compared to controls. A tendency for a normalization of the VSM mass was observed after treatment 
with antigen avoidance (p=0.05), but not with fluticasone (p=0.27). Remodeling of the PA develops 
in SEA and is associated with an increase in VSM. The resulting narrowing of the lumen of the PA 
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could enhance hypoxic vasoconstriction, contributing to PH during exacerbation of SEA. VSM mass 
normalization is better achieved by antigen avoidance than by corticosteroids. 
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PART 1: LITERATURE REVIEW 
 
CHAPTER 1: SEVERE EQUINE ASTHMA 
 
This research project aims to assess presence of pulmonary artery remodeling in severe equine asthma 
and to evaluate whether vascular changes are reversible after long-term asthma treatment. An 
overview about severe equine asthma pathogenesis and clinical consequences, as well as a revision 
of available therapeutic approaches and their efficacy are essential to understand hypothesis and 
results of the experimental study.  
 
DEFINITION AND EPIDEMIOLOGY 
 
Severe equine asthma is a chronic non-infectious obstructive and inflammatory disorder of the equine 
lower respiratory tract, affecting about 10-14% of horses living in the boreal hemisphere (1). 
Reversible bronchospasm due to bronchial hyperresponsiveness, airway neutrophilia, mucus 
increased production, systemic inflammation and pulmonary remodeling are typical features of the 
disease (2). Several terms were used in the past to define this condition including heaves, pulmonary 
disease, broken-wind, emphysema, chronic bronchiolitis, hay sickness, small airway disease, allergic 
airway disease, chronic obstructive pulmonary disease (COPD) and more recently recurrent airway 
obstruction (RAO) (3). Because latest evidences suggest lots of pathophysiological and clinical 
similarities with human chronic asthma, the definition “severe equine asthma” has been officially 
adopted since 2016 (4, 5). Severe equine asthma and human chronic asthma do not totally overlap 
because both are heterogeneous disorders, showing variable clinical presentation and involving 
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complex pathogenetic pathways (4). However, both conditions are reversible and recurrent, with 
alternation between episodes of clinical exacerbation, triggered by exposure to specific environmental 
antigens and periods of disease remission, after removal of the offending antigen (2, 6, 7). During 
exacerbation, the combination of bronchospasm, mucus accumulation and airway remodeling results 
in clinically remarkable airflow obstruction and dyspnea. During remission of the disease, airway 
neutrophilic inflammation regresses and severe asthmatic horses do not clinically differ from healthy 
horses (7). Nevertheless, systemic inflammation as well as structural remodeling of peripheral 
airways are only partially reversible, being responsible for persistence of subclinical airway 
obstruction and for the progressive degenerative nature of the disease (8-11).  
 
ETIOPATHOGENESIS  
 
ETIOLOGY 
 
Severe equine asthma is a multifactorial disorder that involves combination of individual 
predisposition and exposure to environmental exacerbating allergens (2). Severe asthmatic horses are 
likely to have a genetically defective or altered immune response, particularly involving the IL-4/Th2 
mediated pathway. Interestingly, severe equine asthma resulted associated with increased natural 
resistance to gastrointestinal helminths as well as predisposition to allergic skin diseases, that are both 
typical Th2-mediated responses (12). In some families of severe asthmatic Warmbloods, genetic 
studies have identified an association between the sequence of the IL-4 receptor gene and its increased 
expression (13). Although further investigation is required, the immune response of severe asthmatic 
horses is likely to be excessive and/or abnormally persistent towards antigens that are usually 
tolerated by the immune system of healthy horses. Both severe asthmatic and healthy horses develop 
pulmonary neutrophilia after exposure to environmental allergens. Regression of neutrophilic 
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response is observed in healthy horses but not in asthmatics after persistence of the antigenic 
challenge, supporting the hypothesis of individual susceptibility for an abnormal immune response 
(7) Furthermore, other non-genetic factors are associated with increased horse susceptibility such as 
advancing age (≥4 years), breed (Thoroughbreds), pollution, previous respiratory infections, winter 
and spring seasons, early exposure to hay and straw (14, 15).  
In addition to a genetic and individual susceptibility, clinical manifestation of the disease requires 
exposure to specific exacerbating factors that usually consists of inhalation of environmental 
allergens. The pivotal role in inducing exacerbation is played by mold spores particularly belonging 
to Aspergillus fumigatus, Faenia rectivirgula and Thermoactinomyces vulgaris species (16-19). Other 
organic dust components such as bacterial endotoxin as well as inorganic particulate and noxious 
gases are not determinant but contribute to the inflammation degree and clinical syndrome severity 
(20). Because most involved allergens are found in moldy hay, straw and stable dust, severe equine 
asthma has been considered as a “disease of domestication and stabling”. However, less frequently, 
horses may present severe asthma exacerbation following exposure to grass pollen at pasture. This 
syndrome corresponds to what was previously known as Summer-Pasture Associated-RAO (SPA-
RAO) and reflect the variability of antigens that are implicated in the equine asthma-like response, 
similarly to human asthma (4, 21).  
 
PATHOGENESIS 
 
It is widely accepted that severe equine asthma consists in a hypersensitivity reaction to inhaled 
allergens, however specific immunological pathways are far to be completely clarified. Conversely 
to the human disease, an early phase immune response is not implicated in severe equine asthma. 
Although chimase-positive mast cells are increased within airway walls of severe asthmatic horses, 
their role remains unknown, probably contributing to lung tissue remodeling (22). The exacerbation 
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of the disease involves a delayed immune response mediated by CD4+ T-cells, leading to neutrophil 
accumulation into the airways about 5-6 hours after allergen exposure (23).  
Several studies attempted to characterize the Th-type response with controversial results. Most 
evidences suggest a predominant Th2-type response, with increased levels of IL-4 and IL-5 and 
decreased IFNγ, characterizing both the acute and the chronic disease (24-26). Recently, increased 
levels of IL-17 mRNA expression have been demonstrated in the bronchoalveolar lavage fluid 
(BALF) of chronic severe asthmatic horses, suggesting that an involvement of the Th17-type response 
may follow the Th2 type, contributing to maintenance of pulmonary neutrophilia (27, 28). 
Nevertheless, other studies have detected increased levels of IFNγ but not of IL-4 and IL-13, 
suggesting a predominant Th1-type response or increased levels of all the cited cytokines, suggesting 
a mixed Th1/Th2 -type response (29-31). The disagreement among the results may reflect the 
complexity of the immune response in severe equine asthma, suggesting that different T-cell sub-
populations could be involved in different phases. Furthermore, individual genetic susceptibility and 
exposure to variable mixtures of exacerbating allergens may affect the predominant type response, 
supporting the hypothesis that several immunological pathways could be subtended to similar disease 
phenotypes (2).  
Although the involved sub-population and related cytokine expression may vary, T-cell activation 
results in a consistent both airway and systemic inflammatory reaction. Airway inflammation is 
characterized by massive neutrophil chemotaxis as well as enhanced proteolytic activity and 
increased oxidative stress. Early neutrophil recruitment into the airways is related to up-regulation of 
IL-8 gene expression, a well-known neutrophil chemotactic factor, in bronchial epithelial cells, BALF 
derived cells and pulmonary endothelial cells. In vitro evidence suggests that IL-4 induces IL-8 gene 
expression up-regulation as well as peripheral blood neutrophils priming and activation, supporting 
the predominant role of a Th2-type response in the early pathogenesis of severe equine asthma (28, 
32). Both proteolytic activity and reactive oxygen species (ROS) production are enhanced during any 
inflammatory process. Increased release into the airway lumen of neutrophil-derived oxidative 
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enzymes such as myeloperoxidase as well as elevated levels of metalloproteinases (MMPs, including 
MMP-1, MMP-8, MMP-9, MMP-13) secreted by immune and epithelial cells have been detected in 
respiratory secretions of severe asthmatic horses (33-36). A systemic inflammatory reaction is also 
detectable as shown by increased serum levels of some acute phase proteins such as haptoglobin and 
serum amyloid A (37).  
Even though further investigation is required to characterize specific pathways and neutrophil relative 
contribution, the ongoing massive inflammatory reaction induces bronchospasm, increases mucus 
production and initiates airway remodeling, eventually resulting in overall airway obstruction (18). 
Different mechanisms may contribute to airway smooth muscle hyperresponsiveness and 
bronchospasm in severe asthmatic horses, including defections in the noradrenergic and 
nonadrenergic-noncholinergic (NANC) inhibitory systems, hypercontractility related to increased 
expression of neurokinin receptors and enhanced neurokinin-induced bronchoconstriction as well as 
increased release of endothelin-1(38-41). Excessive mucus secretion into airway lumen significantly 
contribute to peripheral airway obstruction in severe equine asthma. Furthermore, its accumulation 
into central airways represents a diagnostic finding that could be clinically detected by endoscopy. 
Both qualitative and quantitative abnormalities are responsible for mucus accumulation. Goblet cells 
hyperplasia and metaplasia are associated with mucus hypersecretion and altered mechanical 
viscoelasticity that prevent effectiveness of the physiological mucociliary clearance (42-44). Both 
mechanical stimulation and inflammatory infiltration contribute to airway remodeling, resulting in 
airway wall thickening, lumen narrowing and bronchoconstriction amplification. Epithelial 
hyperplasia, airway smooth muscle (ASM) cell phenotype switching and enhanced turnover, 
increased collagen deposition represent the most consistent bronchial remodeling events in severe 
asthmatic horses (7, 10, 45, 46).  
Antigen avoidance induces clinical symptom as well as airway neutrophilia remission, however 
subclinical inflammation and airflow obstruction persist. A persistent subclinical inflammatory 
response is detectable not only at the airway level but also at a systemic level, since inflammatory 
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markers remains elevated both in the respiratory secretions and in the serum (9, 34). Deposition of 
disorganized collagen and elastic fibers within the bronchial walls appears not reversible with disease 
remission and contribute to persistent airflow obstruction by decreasing lung elastic compliance (10).  
 
CLINICAL FINDINGS AND DIAGNOSIS 
 
CLINICAL PRESENTATION 
 
The evolutive stage of the disease as well as the complexity of the pathogenesis influence clinical 
presentation, leading to variable degree of symptom severity. Clinical findings include non-specific 
poor performance or exercise intolerance, mild respiratory clinical signs such as cough or more rarely 
mucopurulent nasal discharge and expiratory dyspnea culminating in severe respiratory distress. In 
chronic affected horses, persistent expiratory effort may cause abdominal muscle hypertrophy 
(heaves line). Generalized cachexia may occur, due to significant mismatch between peripheral tissue 
oxygenation and breathing work energy consumption (2). 
The diagnosis of severe equine asthma is easily achieved by clinical examination, supported by 
history of exposure to exacerbating allergens. The most consistent finding detectable at clinical 
examination of severe asthmatic horses is the abnormal breathing pattern, characterized by increased 
expiratory effort, also revealed by nasal flaring and recruitment of accessory abdominal muscle 
during the expiratory phase. In advanced cases, tachypnea may also be present as a reflex response 
to hypoxaemia. Nasal flaring and abdominal effort have been used to elaborate a clinical score 
attempting to estimate the degree of airway obstruction, as shown in table 1 (47). This score reliably 
estimates worsening or post-treatment improving of airway obstruction only in advanced cases, when 
lung dysfunction is severe enough to determine hypoxaemia (total score greater than 5). Although 
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significant lung function deterioration occurs, clinical estimation of airway obstruction is not reliable 
for total scores lower than 5 and lung function tests are required to assess treatment efficacy (48).  
During clinical examination, thorax auscultation usually detects presence of end-expiratory wheezes, 
reflecting the increasing end-expiratory airflow resistance, as well as early inspiratory crackles 
reflecting opening of collapsed alveoli. Auscultation area may result wider because of lung 
hyperinflation and air trapping (2).  
 
ASSIGNED VALUE NASAL FLARING ABDOMINAL EFFORT TOTAL SCORE 
1 No flaring No abdominal component to 
breathing 
- 
2 Slight, occasional 
flaring 
Slight abdominal movement No signs 
3 Moderate flaring Moderate abdominal 
movement 
Mild signs 
4 Severe, continuous 
flaring 
Severe, marked abdominal 
movement 
5 - - Moderate signs 
6 - - 
7 - - Severe signs 
8 - - 
Table 1: Clinical score for severe equine asthma according to Rush et al. (47). Both nasal flaring and increased 
abdominal effort aim to minimize expiratory airflow obstruction. The total clinical score is obtained as the sum of the two 
scores and estimates the severity of airway obstruction. 
 
ANCILLARY DIAGNOSTIC TESTS 
 
Although diagnosis is easy, assessing disease severity and its evolutive stage, evaluating response to 
treatment and defining long-term prognosis still represent a challenge for the clinician and often 
require multiple ancillary diagnostic tests. Furthermore, since importance of airway remodeling in 
the pathogenesis of severe equine asthma has recently emerged, increasing interest has been directed 
to develop diagnostic techniques to assess and quantify the ongoing remodeling process.  
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Lung function assessment 
 
Lung function assessment is particularly useful in those cases of mild-moderate clinical airway 
obstruction, although technical difficulties, such as invasiveness and expensiveness, limit its use 
during routinely practice (2). The most traditional system to assess lung function measures the trans-
pleural pressure variation (∆Ppl), by means of an intra-esophageal catheter and airflow rates, by 
means of a heated pneumotachograph attached to a mask. Lung function indexes are then derived and 
usually include lung resistance, dynamic compliance and related elastance (49). In severe asthmatic 
horses, lung function deteriorates progressively as the degree of airway obstruction worsens. Initially, 
the obstruction limits flow through large and small airways as well as causes irregular ventilation of 
alveoli, inducing an increase of resistance and elastance respectively. Subsequently, to avoid 
excessive airflow reduction, an increase in ∆Ppl occurs. Further increase in resistance and elastance 
reflect airway obstruction worsening related to the disease progression (mucus accumulation and 
airway remodeling) (48).  
 
Blood gas analysis 
 
Arterial blood gas analysis allows evaluating arterial oxygen tension (PaO2)as an estimation of the 
ventilation/perfusion (V/Q) mismatch severity (2). Hypoxaemia is a frequent finding in severe 
asthmatic horses during exacerbation, depending on increased dead space ventilation and related 
pulmonary gas exchange compromise. Increased dead space results from alveolar hyperinflation and 
subsequent compression on pulmonary capillaries that prevents adequate perfusion (50, 51). 
Hypercapnia is not an usual finding in severe asthmatic horses since significant increase in respiratory 
rate and total ventilation ensure maintenance of PCO2 levels within normal ranges (50). 
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Endoscopy 
 
Endoscopic examination of the lower airways is almost systematically performed when severe equine 
asthma is suspected. Mucus accumulation in the tracheal lumen and thickness of the tracheal carina 
could be visually examined during tracheoscopy, even though clinical significance of these findings 
should be critically evaluated. An endoscopic score for mucus accumulation has been elaborated, 
showing a good correlation with airway neutrophilic inflammation (52). However, one should remind 
that mucus is a non-specific marker and other disorders resulting in lower airway inflammation may 
be associated with mucus accumulation. An endoscopic scoring system has been proposed also for 
carina thickness but no significant correlation with the degree of airway inflammation has been 
demonstrated (53). In addition to allowing direct visualization of the airways, transendoscopic 
techniques are available to collect cytological and histological samples and more recently to 
investigate airway structure by ultrasonography.  
 
Bronchoalveolar lavage fluid (BALF) cytology 
 
BALF cytology still represent the gold standard to assess presence of lower airway inflammation and 
to characterize the inflammatory profile (2). Although BALF cytological composition may vary 
according to several individual and environmental factors, severe asthmatic horses in exacerbation 
usually show a typical cytological differential count characterized by elevated neutrophil percentage 
(usually greater than 25%) and decrease of lymphocyte and macrophage relative counts (54). 
Nevertheless, BALF cytology and particularly neutrophil count does not correlate with severity of 
clinical airway obstruction and lung dysfunction. This is further supported by response to 
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corticosteroid therapy, characterized by significant improvement of clinical signs and airway 
obstruction without reduction of airway neutrophilia, achieved only with antigen avoidance (8). 
 
Endobronchial biopsy 
 
Endobronchial biopsies could be easily collected during bronchial endoscopic examination using a 
transendoscopic smooth oval forceps. Endobronchial biopsy evaluation allows estimation of ongoing 
central airway remodeling by assessing histological changes within airway ephitelium, basal 
membrane, sub-mucosal and smooth muscle layers. A semiquantitative histological score has been 
recently developed, showing a good correlation between severity of central airway remodeling and 
degree of airway obstruction (55).  
 
Imaging techniques 
 
Thoracic radiography may show non-specific diffuse increased bronchial and interstitial pattern. 
However, diagnostic value of this technique is questionable since similar radiographic changes may 
occur related to ageing. Furthermore, presence of severe equine asthma may be associated to normal 
thoracic radiography. Recently, transendoscopic endobronchial ultrasonography (EBUS) has been 
validated in horses. This technique allows non-invasive and reliable estimation of airway smooth 
muscle remodeling in severe equine asthma. However, equipment expensiveness and technical 
difficulties related to procedure realization and data interpretation limit the use of this technique to 
the research field (56).  
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THERAPY 
 
Severe equine asthma is an incurable disease and all the available therapeutic options are aimed to 
control clinical signs typical of exacerbation and to decelerate the disease progression. The main 
therapeutic goals are reducing airway inflammatory response and limiting airway obstruction (2). 
Two main groups of strategies are available: the antigen avoidance strategy and the pharmacological 
strategy.  
 
ANTIGEN AVOIDANCE STRATEGY 
 
The antigen avoidance strategy consists of management changes aimed to minimize the risk of 
exposure to exacerbating allergens. Ideally, severe asthmatic horses should be maintained at pasture 
(with the exception of those horses affected by pasture-associated forms). When stabling is 
unavoidable, managerial efforts should be pursued to limit exposure to airborne dust, including use 
of low-dust bedding, administration of forage other than hay (such as haylage, chopped dry forage, 
alfalfa, silage or cubed diets), improvement of stable ventilation (2). The antigen avoidance strategy 
represents the most effective and complete therapeutic approach because allows visible reduction of 
clinical signs within 3 days, progressive improvement of lung function, regression of airway 
neutrophilic inflammation, reduction of IL-8 mRNA expression and gradual reversibility of ASM 
remodeling (although the ASM remains about 30% increased compared to healthy horses) (8). 
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PHARMACOLOGICAL STRATEGY 
 
Corticosteroids 
 
Corticosteroids remain the elective drug choice to control severe equine asthma. Effective routes are 
parenteral (intravenous or intramuscular) administration and inhalation. The most common 
parenterally administered corticosteroid is dexamethasone (0.01-0.08 mg/kg) (57). Other 
corticosteroids which efficacy has been assessed after parenteral administration include triamcinolone 
acetonide (0.09 mg/kg) and isoflupredone acetate (0.03 mg/kg) (58, 59). Administration via 
inhalation limits systemic side effects (laminitis and adrenal suppression), while providing high drug 
concentrations within the airways (60). The most studied inhaled corticosteroids are beclomethasone 
dipropionate and fluticasone propionate. Beclomethasone dipropionate (500 µg-1320 µg q12 h) 
induces a dose-dependent adrenal suppression, showing variable efficacy compared to parenteral 
dexamethasone according to different studies (47, 61, 62). Fluticasone propionate (6 mg q 12h) 
administration, although resulting in a slightly reduced efficacy in improving airway obstruction is 
associated with significant lower side effects on adrenal function compared to parenteral 
dexamethasone and represent the most used inhaled corticosteroid (63). Corticosteroid treatment 
allows similar reduction of clinical signs compared to antigen avoidance, although horses remain 
exposed to exacerbating allergens. Furthermore, corticosteroid administration result in faster 
improvement of lung function, although incomplete, because an additional improvement could be 
obtained only by the antigen avoidance strategy. The reduction of ASM achieved by corticosteroid 
administration is similar to that obtained with antigen avoidance but is more rapid. However, 
corticosteroids are not efficacious in controlling airway inflammation, since pulmonary neutrophilia 
and level of IL-8 mRNA expression remain elevated even after long-term fluticasone administration 
(6 months) (8).  
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Bronchodilators 
 
Bronchodilators have been largely employed in severe equine asthma treatment. An effective 
inhibition of bronchospasm and related airway obstruction may be achieved by adrenergic stimulation 
(sympathomimetics) or cholinergic/muscarinic antagonization (parasympatholytics) respectively. 
Bronchodilators are often administered as emergency drugs in severely affected horses or as pre-
treatment that facilitates subsequent deep penetration and deposition of inhaled corticosteroids (64). 
Sympathomimetics mainly include β2-adrenergic agonists that may be administered systemically or 
via inhalation. Clenbuterol is usually administered orally and combined to corticosteroid, to avoid β2-
receptor downregulation and response decrease, a typical side effect of alone administered clenbuterol 
(tachyphylaxis) (65). Alternatively, some sympathomimetic bronchodilators may be administered via 
inhalation, including albuterol sulfate and salmeterol xinafoate. Albuterol sulfate is a short-acting β2-
adrenergic agonist having good efficacy in inducing rapid bronchodilatation (within 5 minutes after 
administration) with negligible systemic side effects. However, its effect is short, lasting variably 
between 30 minutes and 3 hours and requiring frequent administration (720 µg 3-4 times/day) (66). 
Salmeterol xinafoate (210 µg once-twice/day) is a long-acting β2-adrenergic agonist which 
bronchodilation effect onset is delayed compared to albuterol (30-60 minutes after administration) 
but lasts longer (about 6 hours) (67). It is more indicated for long-term control of severe equine 
asthma, especially whether combined to fluticasone. A recent study showed that long term treatment 
with combinations of inhaled salmeterol and fluticasone are more effective than fluticasone alone in 
controlling clinical signs and airway neutrophilia, while no differences were detected regarding the 
effect on airway remodeling (68).  
Parasympatholytic drugs which bronchodilator effect has been assessed in severe asthmatic horses 
include both anticholinergics and antimuscarinics. Anticholinergics include atropine and the anti-
spasmodic N-butylscopolammonium bromide that are both administered systemically, providing 
rapid and efficacious bronchodilation. However, their clinical use is limited for different reasons. 
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Atropine has severe and significant systemic side effects while N-butylscopolammonium bromide has 
fewer side effects, however showing too short effect last (69, 70). The most used antimuscarinic is 
the non-selective ipratropium bromide (1.8-3.6 mg twice-three times/day). It could be administered 
via inhalation inducing efficacious bronchodilation with a quite long-lasting action and no significant 
systemic side effects (71). The selective M1-M3 antimuscarinic revatropate (1.2-7 mg) has been also 
assessed in horses, inducing significant bronchodilation. However, no significant advantages are 
shown compared to non-selective drugs (72).  
 
Other drugs 
  
Several molecules have been evaluated aiming to discover alternatives that could be as efficacious as 
corticosteroids in controlling clinical signs, but also capable to reduce airway inflammation. 
Unfortunately, most molecules targeting specific immunological pathways, such as p38 MAPK 
inhibitors, PDE4 inhibitors, cysteinyl-leukotriene antagonists appearing promising in experimental 
rodent models of asthma, did not show any significant efficacy in spontaneous severe equine asthma 
(4). Considering the emergent importance of ASM remodeling in determining disease progression, 
future therapeutic investigation could be target ASM proliferation, with the aim of reducing its mass 
(7). 
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CHAPTER 2: PULMONARY HYPERTENSION 
 
In severe equine asthma, pulmonary hypertension (PH) is described as complication occurring during 
clinical exacerbation of the disease. However, accurate assessment of pulmonary artery pressure in 
horses is challenging, limiting clinical investigation about PH occurrence, its clinical impact and 
pathophysiology. In humans, PH represents a typical end-stage complication of some chronic 
respiratory disorders and its pathophysiology has been extensively investigated in cardiorespiratory 
medicine. Pulmonary vascular remodeling, defined as structural and compositional change of the 
pulmonary vessel wall, represents a key determining factor in the pathophysiology of PH, particularly 
in those forms associated with chronic respiratory disorders. An overview of human PH, especially 
concerning PH associated with lung disease, is provided in this chapter, highlighting the role of 
pulmonary vascular remodeling in its pathophysiology, supporting the hypothesis that similar 
mechanisms may be involved in severe equine asthma. 
 
PULMONARY HYPERTENSION AND CHRONIC RESPIRATORY 
DISORDERS IN HUMAN MEDICINE 
 
DEFINITION  
 
Pulmonary hypertension (PH) is a pathological hemodynamic condition characterized by an increase 
in the mean pulmonary artery pressure (mPAP) above the range of physiological values. The mPAP 
is the mean between systolic and diastolic PAP, normally varying between 20 and 30 mmHg and 
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between 8 and 12 mmHg, respectively. In humans, the mPAP at rest is about 14.0 ±3 mmHg, with a 
normal upper limit of about 20 mmHg both for standing and supine positions (73).  
According to the European Society of Cardiology and the European Respiratory Society guidelines, 
to define clinically the presence of PH, the mPAP must respect three different criteria: 1) it must be 
higher than 25 mmHg, 2) assessed at rest and 3) measured by right heart catheterization (74). 
Although the normal upper limit of mPAP is 20 mmHg, patients whose mPAP is between 21 and 
24 mmHg are not considered hypertensive but they should be monitored, particularly when belonging 
to risk categories for development of pulmonary arterial hypertension (PAH) (75). 
Diagnosis of PH is based on mPAP measured at rest because a reliable threshold between 
physiological and pathological increase in mPAP values during exercise is still impossible to be 
defined. Therefore, according to the current guidelines, a definition of “PH on exercise” is not 
accepted anymore (74). In any case, a resting mPAP between 21 and 24 mmHg seems closely 
associated with PH on exercise, when a combination of a mPAP greater than 30  mm Hg and 
a total pulmonary resistance, calculated as mPAP/cardiac output ratio, greater than 3 Wood units 
(WU) is detected at maximal exercise (76, 77).  
Although right heart catheterization is invasive, it is the gold standard for the diagnosis of PH, 
especially when treatment is considered. Echocardiographic continuous wave Doppler 
technique allows to assess peak tricuspid regurgitation, from which an estimation of the mPAP 
could be obtained and used to determine the likelihood of PH. This technique is noninvasive 
and useful in clinical settings where it is performed as a screening test for patients suspected 
of PH. However, it does not provide the accurate measurement needed to support a treatment 
decision on an individual basis.  
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CLASSIFICATION 
 
The classification of PH proposed in 1973, differentiated primary and secondary PH, according to the 
presence of identified causes or risk factors (78).  In 1998, a more clinical approach was elaborated, 
aiming to classify the disease into groups sharing similar clinical presentations, pathological findings, 
and therapeutic strategies (79). This general classification scheme is still accepted today, having been 
revalidated in the most recent guidelines (74). Five groups of clinical disorders associated to PH are 
defined:  
• Group 1: pulmonary arterial hypertension (PAH) 
• Group 2: pulmonary hypertension due to left heart disease 
• Group 3: pulmonary hypertension due to chronic lung disease/hypoxia 
• Group 4: chronic thromboembolic pulmonary hypertension 
• Group 5: pulmonary hypertension due to unclear multifactorial mechanisms 
However, different clinical groups share similar hemodynamic characteristics, therefore a wider 
distinction between pre-capillary and post-capillary PH is also reported. For this classification, 
different hemodynamic parameters obtained by right heart catheterization are considered in addition 
to mPAP, including the cardiac output (CO), the pulmonary arterial wedge pressure (PAWP), the 
pulmonary vascular resistance (PVR) and the diastolic pressure gradient (DPG). The CO represents 
the blood volume pumped by the ventricle per minute and it is calculated by multiplying the stroke 
volume by the heart rate. The physiological CO varies between 4 and 8 liters per minute. The PAWP 
indirectly estimates the left atrial pressure and it measured by wedging the catheter with an inflated 
balloon into a small pulmonary arterial branch. Normal PAWP values vary between 4 and 12 mmHg. 
The PVR reflects the right ventricle afterload and it is calculated as the difference between the mPAP 
and the PAWP, divided by CO. Normally, PVR range is 0.3-1.6 Woods Units (WU). The DPG is a 
novel parameter calculated as the difference between the diastolic PAP and the mean PAWP, showing 
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low sensitivity to changes in loading conditions thereby serving as a robust marker for pre-capillary 
pulmonary vascular remodeling (80). 
Pre-capillary PH includes all the PH conditions characterized by a PAWP value lower than 15 mmHg, 
with normal or reduced CO. Group 1, group 3, group 4 and some group 5 disorders are associated 
with pre-capillary PH. Conversely, post-capillary PH include all the PH conditions characterized by 
a PAWP value greater than 15 mmHg, with normal or reduced CO. Group 2 and some group 5 
disorders are associated as post-capillary PH. A further sub-classification of post-capillary PH can be 
made according to the PVR and DPG values. Isolated post-capillary PH (Ipc-PH) refers to those post-
capillary PH disorders characterized by a DPG value lower than 7 mmHg and/or a PVR value lower 
than 3 WU. In these cases, the primary left-sided cardiac condition is the only responsible for the PH 
and no pulmonary vascular remodeling is occurring. Combined post-capillary and pre-capillary PH 
(Cpc-PH) occurs when DPG value is equal or greater than 7 mmHg and/or PVR value is equal or 
greater 3 WU. In these cases, a primary left-sided cardiac condition inducing post-capillary PH, is 
associated to evidence of pulmonary vascular remodeling that add a pre-capillary PH component (81).  
Table 1 summarizes classification criteria of PH, according to the most recent guidelines (74). 
A more detailed description of group 3 disorders will be provided below, including epidemiology, 
pathophysiology and clinical implications of respiratory diseases associated to PH. 
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HEMODYNAMIC CLASSIFICATION CLINICAL CLASSIFICATION 
Pre-capillary 
PH 
 
mPAP > 25 mmHg 
PAWP < 15 mmHg 
Group 1: Pulmonary Arterial 
Hypertension 
Group 3: Chronic lung 
disease/hypoxia PH 
Group 4: Chronic thromboembolic 
PH 
. Group 5: Unclear multifactorial PH 
Post-capillary 
PH 
 
mPAP > 25 mmHg 
PAWP > 15 mmHg 
Ipc-PH: 
DPG < 7 mmHg  
PVR < 3 WU 
 
 
Group 2: Left heart disease PH 
Cpc-PH: 
DPG > 7 mmHg  
PVR > 3 WU 
Table 2: Classification of pulmonary hypertension (PH). mPAP =mean pulmonary artery pressure; PAWP= pulmonary 
arterial wedge pressure; DPG =diastolic pressure gradient; PVR = pulmonary vascular resistance; Ipc-PH = isolated 
post-capillary pulmonary hypertension; Cpc-PH = combined pre-capillary post-capillary pulmonary hypertension (74). 
 
CLINICAL IMPLICATIONS 
 
Persistent PH predominantly increases the right ventricle (RV) afterload, that is the load against which 
the right ventricle must eject its volume of blood during contraction. The “RV afterload” depends on 
the pulmonary vascular load, such as the pulmonary vascular resistance and the blood volume, flow 
pulsatility, wave reflections through the pulmonary vascular system (82). The RV afterload is 
estimated by the pulmonary arterial elastance (Ea), defined as the change in pressure for a change in 
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volume, effectively representing the arterial load that the ventricle should overcome during ejection 
(82). Persistent increase in afterload affects RV structure and function, determining its remodeling 
and adaptation with progressive clinical evolution of PH (83). Progressive RV remodeling usually 
consists of an initial compensatory hypertrophy, that later progresses to maladaptive enlargement, 
until right heart failure (84). In case of group 3 PH, right heart involvement characterized by 
hypertrophy, dilatation or both is known as cor pulmonale (85). Right ventricle dysfunction is the 
most important determinant of PH long-term prognosis, since PH patients with higher mean right 
atrial pressures and lower cardiac output have significantly poorer survival rate (86). The evolution 
time from RV adaptation to RV failure is variable and is related to the response of myocardial tissue 
more than the amount of pressure overload (84).  
In early PH stages, there is no RV dysfunction at rest and clinical evidence of cardiac involvement is 
limited to exercise intolerance, due to impaired “right ventricular exertional contractile reserve”. The 
“right ventricle contractility” is an estimation of right ventricle pump performance, such as the degree 
to which myocardial fibers can shorten, independently from preload and afterload. It can be expressed 
quantitively by the right ventricle-end systolic elastance (Ees), i.e. the slope of the linear relationship 
between end-systolic pressure and volume, obtained by changes in ventricular filling (82, 83). The 
ratio between right ventricle contractility, expressed as Ees, and right ventricle afterload, expressed 
as Ea, and, is defined as “right ventricle-pulmonary arterial coupling” and represents a marker of 
ventricular efficiency (87). The adaptive compensatory mechanism to increased right ventricle 
afterload in early PH stages, is an increase of right ventricle contractility, via an enhancement of 
intrinsic cardiomyocyte contractile properties and via muscular hypertrophy (83, 84). The activation 
of sympathetic and renin angiotensin aldosterone system (RAAS) in response to short term pressure-
overload play a pivotal role for maintaining in enhancing RV contractility. It has been suggested that 
the RV first adapt occurs through concentric hypertrophy and eventually evolves into eccentric 
hypertrophy (84). At rest, PH affected patients show similar right ventricle-pulmonary arterial 
coupling, preserved ventricular efficiency and unaltered ventricle volumes, compared to healthy 
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controls (87). Since no chamber dilatation occurs, the increase in contractility is defined as 
“homeometric” RV adaptation (Naijé et al. 2014). Right ventricle hypertrophy may be reversed by a 
decrease of RV afterload, although it is not clear whether the RV function is also restored (84). 
 During exercise, the increase of metabolic demand induces concomitant increase in heart rate and 
stroke volume. In healthy subjects, the increased stroke volume stimulates pulmonary vessel passive 
recruitment and distension, preventing excessive increase of the right ventricular afterload and 
resulting in increased cardiac output, enhanced pulmonary perfusion and gas exchanges. The 
“ventricular exertional contractile reserve” is defined as the magnitude from basal to maximal cardiac 
power output in response to exercise (88). In PH affected patients, a greater increase in afterload 
occurs during exercise because of limited passive distension of pulmonary vessels, decreasing right 
ventricle-pulmonary arterial coupling and ventricular efficiency. The impairment of the exertional 
contractile reserve prevents adequate increase of cardiac output, appearing as clinical exercise 
intolerance (87). 
In more severe PH stages, the increase of right ventricle contractility is not sufficient to match the 
increased afterload. As the load progressively increases, the stroke volume and the ejection fraction 
decrease, with inactivation of the hypertrophic response and systolic dysfunction (82, 84). Failure of 
systolic function is associated to the RV “heterometric” maladaptive state, characterized by 
progressive RV dilatation and remodeling leading to right ventricle and chronic right heart failure 
(83). Several mechanisms, including genetic predisposition, neurohormonal overactivation and RV 
ischemia could trigger the transition from an adaptive to a maladaptive state, characterized by 
cardiomyocyte contractile dysfunction, progressive myocardial inflammation and fibrosis (82, 84). 
The sarcomeric stiffening associated to myocardial fibrosis is responsible for further deterioration of 
RV diastolic function and progression to end-stage right heart failure. Systolic and diastolic 
dysfunctions limit RV flow output, increase right-sided filling pressures, with the appearance of a 
congestive right heart failure clinical syndrome, and decrease the left-sided filling, with eventual 
lowering of the systemic arterial blood pressure (83).  
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DIAGNOSIS 
 
Diagnosis of pulmonary hypertension may be challenging since most frequent clinical symptoms are 
related to progressive failure of the right ventricle and they are often non-specific. Furthermore, early 
clinical signs are not detectable at rest but mainly appear as a general exercise intolerance, with 
shortness of breath, fatigue, weakness, angina and syncope occurring during the effort and less 
commonly exercise-induced nausea and vomiting. With the progression of the disease severity, these 
symptoms are also detectable at rest and the end-stage disease consists of a congestive right heart 
failure, associated with abdominal distension and peripheral edema.  
As suggested by the most recent guidelines, when PH is suspected, a systematic approach should be 
adopted aiming to confirm the haemodynamic changes, to identify the clinical classification group 
with the possible etiology, and to assess the condition severity (74). First, diagnostic confirmation of 
PH requires assessment of mPAP and other haemodynamic parameters. As mentioned above, the 
initial screening test is performed using echocardiography while the definitive diagnosis is achieved 
by right heart catheterization. Other ancillary diagnostic tests that may be useful to investigate the 
PH-associated clinical disorders, include routine hematology and biochemistry, electrocardiography, 
pulmonary function tests, arterial blood gas analysis, immunology, basic and advanced imaging 
techniques (chest radiography, ventilation/perfusion lung scans, high-resolution computed 
tomography, cardiac magnetic resonance imaging).  
Transthoracic echocardiography is the least invasive tool to estimate PAP and is recommended as 
preliminary diagnostic test in patients suspected of PH, based on history and clinical signs. In absence 
of pulmonary valve outflow obstruction, systolic PAP corresponds to right ventricular systolic 
pressure (RVSP) and may be estimated from continuous wave Doppler measurements. The RVSP 
can be calculated by measuring the peak tricuspid regurgitation velocity (TRV) and estimating the 
right atrial pressure (RAP), according to the simplified Bernoulli equation RVSP=4(TRV)2+RAP 
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(89). However, RAP could be only approximately estimated, therefore the direct TRV measurement 
is more accurate than the RVSP calculation to assess the level of PH probability in suspected 
symptomatic patients. When TRV is not measurable, lower than or equal to 2.8 m/s using 
transthoracic echocardiography, the probability of PH is low; when TRV is greater than 3.4 m/s 
probability of PH is high. When the TRV varies between  2.9 and 3.4 m/s the PH probability level 
may be intermediate or high depending of the presence of additional echocardiographic abnormalities 
affecting the ventricles (such as increased right ventricle/left ventricle ratio and flattening of the 
interventricular septum), the pulmonary artery (such as decreased right ventricle outflow Doppler 
acceleration time, increased early diastolic pulmonary regurgitation velocity and increased 
pulmonary artery diameter) or the right atrium/inferior vena cava (such as increased inferior vena 
cava diameter with decreased respiratory collapse, increased right atrial area) (74). Criteria for 
echocardiographic PH probability level assignation are resumed in table 2. However, inaccuracy in 
estimating the PH risk could occur. In patients with severe tricuspid regurgitation, the TRV may be 
technically difficult to measure and significantly underestimated, therefore it could not be used to 
rule out PH. Conversely, overestimation could also occur, therefore echocardiographic TRV alone is 
not a reliable screening tool for PH in asymptomatic or mild symptomatic patients (90, 91). 
Furthermore, although a presumptive diagnosis of PH may be based on echocardiographic findings 
in symptomatic patients, PH definitive diagnosis and treatment decision always requires confirmation 
by right heart catheterization. From a clinical point of view, echocardiography is useful to select those 
symptomatic patients that are likely to be affected by PH and should undergo further invasive 
investigation by right heart catheterization. In addition, some echocardiographic findings are 
suggestive for specific etiology in case of confirmed PH, especially for group 2 cardiac disorders.  
The PH probability level is used to further orient the diagnostic approach in symptomatic patients. 
When the probability is low, causes of exercise intolerance other than PH should be considered and 
ruled out. When the probability of PH is intermediate or high, the suspicion merits investigation. In 
this case, one should investigate whether some clinical disorders typically associated to PH occur or 
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not. Chronic lung diseases (group 3) or left side chronic heart failure (group 2) could be detected by 
electrocardiography, pulmonary function tests, arterial blood gas analysis, chest radiography and 
high-resolution computed tomography. If group 2 or group 3 clinical disorders are diagnosed, the 
severity of PH-associated clinical signs should be evaluated. If they are mild or negligible, treatment 
could be focused only on the underlying disease; if symptoms are severe, PH itself should be treated 
and right heart catheterization is required to optimize the treatment choice. If group 2 and group 3 
disorders are ruled out, the presence of other clinical disorders (group 1,4 and 5) should be 
investigated. An V/Q scan is the method of choice to assess group 4 CTEPH. This technique has an 
excellent sensitivity; therefore, a normal V/Q scan can rule out CTEPH. However, unmatched 
perfusion defects may be present also in group 1 clinical disorders (92). Definitive differential 
diagnosis must rely on other diagnostic test results, such as contrasted computed tomography 
angiography of the pulmonary artery, that can delineate the typical angiographic findings of CTEPH, 
including complete obstruction, bands and webs and intimal irregularities (93-95). If diagnosis of 
CTEPH is confirmed, traditional pulmonary angiography is required to evaluate which patients may 
benefit of elective lung surgery. Similarly, right heart catheterization might be also necessary for 
those patients already showing severe PH clinical signs, for prognosis and therapeutic approach 
evaluation. If CTEPH is ruled out, suspicion of group 1 PAH disorders becomes consistent. Serology, 
genetics and other specific diagnostic tests are required to differentiate etiologies of disorders 
belonging to group 1. When PH is confirmed with right heart catheterization, but etiology remains 
undiagnosed, patients are assigned to clinical group 5.  
Right heart catheterization remains the gold standard to confirm PH diagnosis, to assess the severity 
of haemodynamic impairment and to perform vasoreactivity testing of the pulmonary circulation in 
to identify suitable candidates for treatment with high-dose calcium channel blockers. In patients 
showing post-capillary PH (elevated PAWP) in absence of echocardiographic signs of left heart 
disease (preserved ejection fraction, normal left atrial size and absence of markers of elevated left 
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ventricle filling pressures), a left heart catheterization may also be required to determine whether 
inaccuracy of PAWP occurs, by directly measuring the left ventricle end-diastolic pressure.  
 
TRV measurement (m/s) Other echocardiographic signs  Level of PH probability 
≤ 2.8 or not measurable 
NO Low 
YES 
Intermediate 
2.8 < TRV < 3.4 
NO 
YES 
High 
>3.4 NOT REQUIRED 
Table 3: Echocardiographic criteria for assignation of pulmonary hypertension (PH) probability level. 
Echocardiographic additional signs may be detected from at least two of the three echocardiographic districts including 
the ventricles, the pulmonary artery and the inferior vena cava/right atrium. 
  
CHRONIC LUNG DISEASE/ HYPOXIA-ASSOCIATED PULMONARY HYPERTENSION 
 
Definition, classification and epidemiology  
 
Group 3 PH occurs when the mPAP increase greater than 25 mmHg is related to respiratory 
abnormalities, such as chronic parenchymal lung diseases or persistent hypoxia. The condition may 
be further classified as “severe” when one of two following situations occurs: the mPAP is greater 
than 35 mmHg or the mPAP is lower than 35 mmHg, but associated with a low cardiac index (inferior 
than 2.5L/min/m2) not explained by other causes (74, 96). Lung diseases that are associated with PH 
include Chronic Obstructive Pulmonary Disease (COPD), Interstitial Lung Diseases (ILD), 
Connective Tissues Disease (CTDs) involving the lung, Sarcoidosis, Idiopathic Pulmonary Fibrosis 
(IPF), Lymphangioleiomyomatosis (LAM) and Combined Pulmonary fibrosis and Emphysema 
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(CPFE) (97). All these disorders may evolve without the appearance of PH. However, development 
of PH is negative prognostic factor that is significantly associated with deterioration of exercise 
capacity, worsening of hypoxemia, reduced response to treatment and shorter survival (98, 99).  
Pulmonary hypertension represents the most common end stage complication of both severe ILD and 
severe COPD. However, there is no correlation between the severity of the lung disorder and the 
severity of the associated PH. In most cases, PH is mild or moderate while severe PH is rare, mainly 
occurring in the CPFE, where the overall prevalence of PH is high. In one survey study, among PH 
affected patients showing mPAP greater than 40 mmHg, only 9.7% belonged to clinical group 3 (97). 
Therefore, it is unlikely that a mild lung disease is associated to severe PH. If this combination is 
detected, other groups of clinical disorders (particularly group 2 and 4) causing PH could be present 
in addition to lung disease and should be investigated. In patients with COPD, serotonin transporter 
gene polymorphism appears to be related the severity of PH. Patients carrying genotypes associated 
with high serotonin transporter expression in pulmonary artery smooth muscle cells show 
significantly higher smooth muscle hyperplasia, with development of more severe PH (100).  
 
Physiopathology  
 
In physiology, the pulmonary circulation is defined as “low pressure circulation system” because 
vascular pressure values are much lower compared to systemic circulation, although both systems 
receive the same cardiac output flow. The blood driving pressure is directly influenced by vascular 
resistance which regulation mechanisms highly differ between the two circulation systems. 
Pulmonary vascular resistance (and the associated driving pressure) is inversely proportional to the 
cardiac output flow, because, unlike the systemic circulation, the vasomotor activity of pulmonary 
vessels is limited.  
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Regulation of pulmonary regional blood flow mainly occurs at pulmonary capillaries which represent 
the largest percentage of the pulmonary vascular surface. No smooth muscular layer is detectable 
within the pulmonary capillary wall, therefore vascular resistance regulation occurs through passive 
vasoconstriction and vasodilation, depending on alveoli inflation status and blood flow through the 
lung. In physiological conditions, pulmonary circulation adapts to large changes in cardiac output by 
distension or recruitment of under-perfused pulmonary capillaries, meaning that as the pulmonary 
blood flow increases, the pulmonary vascular resistance and pressure decrease. 
Increase in pulmonary vascular resistance by active vasoconstriction may occur as an adaptive 
mechanism only for extra-alveolar precapillary vessels (arterioles and muscular pulmonary arteries), 
in response to specific nervous, humoral and particularly gaseous stimuli such as hypoxia (101). 
Hypoxic pulmonary vasoconstriction (HPV), also known as von Euler-Liljestrand mechanism, is a 
reflex mechanism that optimizes the ventilation/perfusion matching, in case of regional acute or 
sustained hypoxia. Alveolar hypoxia as well as a drop in pulmonary arterial oxygen tension (PaO2) 
directly induce local pulmonary artery vasoconstriction, diverting blood flow from unventilated 
hypoxic areas toward better ventilated lung regions. HPV is triggered by intrinsic mechanisms, 
involving pulmonary artery smooth muscle cells (PASMC) and endothelial cells. In acute HPV, the 
oxygen sensing-signaling pathway is completely located in PASMC and adapts perfusion to 
ventilation in seconds, on a breath-to-breath basis. A change in PASMC redox state due to a 
modification in reactive oxygen species (ROS) content of PASMC mitochondria is the most likely 
transduction pathway, since ROS production is an oxygen-dependent process that is rapidly modified 
according to oxygen tension. However, whether the cause of HPV is an increased or a decreased ROS 
production and how the cellular redox state may activate smooth muscle contraction cascades are not 
clear and still debated (102-106). Sustained HPV, occurring when hypoxic ventilation lasts more than 
10 minutes, involves transduction mechanisms related to PASMC energetic metabolism, particularly 
a shift from aerobic mitochondrial ATP production to predominant anaerobic glycolysis (107, 108). 
Definitively, both a change in the PASMC redox status and/or an enhanced PASMC anaerobic 
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metabolism trigger PASMC intracellular calcium release, resulting in myosin light chain 
phosphorylation and contraction. The myosin light chain phosphatase mediates de-phosphorylation 
with myorelaxation and vasodilation. Sustained hypoxia also activates endothelial signaling 
pathways, such as endothelial membrane depolarization in alveolar capillaries. The signal is 
propagated upstream through the endothelial layer in a connexin-40-dependent manner and is 
necessary for pre-conditioning PASMC to execute sustained HPV. An endothelium-dependent rho-
kinase activation could inhibit the myosin light chain phosphatase, inducing sensitization and 
persistent vasoconstriction in sustained HPV (109). Although triggered by PASMC or endothelium 
intrinsic mechanisms, HPV can be modulated by extrinsic systemic neural, humoral and physical 
factors, which play a role in pathological conditions (110).  
During parenchymal chronic lung disease, pathological changes involve mechanical, structural and 
biochemical/reflexive factors, as summarized in table 3. Although the contribution of single factors 
depends on the specific underlying disease, these changes enhance active vasoconstriction and 
prevent passive vasodilation, resulting in an overall increase of pulmonary vascular resistance and 
onset of PH (97, 101).  
Mechanical factors include alveolar hyperinflation and increased blood viscosity. Alveolar 
hyperinflation significantly contributes to PH in advanced COPD (111) Chronic bronchitis reduces 
airway lumen, limits expiratory airflow and determines lung air trapping, increasing intra-alveolar 
volume and pressure. Increase of alveolar air volume stretches capillaries lying within the alveolar 
wall, with reduction of their diameter and increase in their length. The consequence is a great increase 
in capillary resistance, because vascular resistance is directly proportional to vascular length and 
inversely proportional to vascular radius to the fourth power. Furthermore, increased intra-alveolar 
pressure directly compresses pulmonary capillaries, limiting passive recruitment and distension in 
response to pulmonary blood flow augmentation (112). Chronic hypoxemia occurs in several chronic 
lung diseases and stimulates secondary polycythemia, with increased blood viscosity that is 
associated to increased vascular resistance in a directly proportional manner (113). 
32 
 
Structural factors refer to remodeling and re-distribution of pulmonary vessels. Remodeling is the 
predominant cause of increase in vascular resistance in all chronic lung disease associated to PH. 
Furthermore, remodeling represents the main cause of PH unresponsiveness to oxygen therapy in 
these disorders. The common consequence of different remodeling processes is vascular wall 
thickening that involves predominantly small pulmonary arteries and, in conditions such as 
sarcoidosis, also pulmonary venules (114, 115). Wall thickening increases vascular resistance by 
reducing vascular lumen diameter and favoring vascular stiffness, with the limitation of passive 
distension. Some respiratory disorders (such as COPD and pulmonary fibrosis) and chronic hypoxia 
(116) are also characterized by vascular smooth muscle hypertrophy/hyperplasia and distal arteriolar 
neo-muscularization. These events contribute to PH onset, by reducing distal vessel compliance but 
also enhancing global lung response to HPV. Re-distribution of pulmonary vessels include loss of 
pulmonary vascular bed due to emphysema or fibrosis associated to abnormal angiogenesis (101). 
Emphysema typically occurs in COPD and is defined as an irreversible abnormal enlargement of lung 
air space due to progressive destruction of alveolar walls, that also involve destruction of alveolar 
capillaries. In IPF, severe fibrosis also involves intimal layer of pulmonary capillaries, leading to 
vascular obliteration. Furthermore, chronic hypoxia, lung parenchymal destruction and inflammation 
stimulate vascular pericytes to release pro-angiogenetic mediators, such Vascular Growth Endothelial 
Factor (VGEF), Transforming Growth Factor β (TGFβ) and Platelet Derived Growth Factor (PDGF). 
These factors induce angiogenesis by stimulating proliferation of endothelial cells (117). However, 
newly produced vasculature is structurally abnormal, having less capability of passive distension 
compared to normal pulmonary capillaries. Destruction or obliteration of pulmonary capillaries and 
abnormal angiogenesis prevent adequate vascular recruitment when cardiac output increases, 
contributing to enhanced vascular resistance and effort intolerance during exercise conditions (118). 
Re-distribution of pulmonary vessels plays a minor role compared to vascular remodeling in the 
pathophysiology of PH at rest, especially in mild-moderated disease. It has been shown that the extent 
of emphysema in COPD, evaluated as lung density in vivo by CT scans, is not correlated to the 
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severity of PH at rest, assessed as measured mean pulmonary arterial pressure, cardiac output, or 
calculated total pulmonary vascular resistance. However, in end-stage disease, emphysema represents 
the major determinant of PH and significantly affects gas exchange surfaces and arterial 
oxygenation.(111, 119).  
Biochemical/reflexive factors include pathological sustained HPV and pulmonary vascular 
endothelial dysfunction. Local acute HPV is a protective mechanism, but becomes detrimental when 
sustained and activated in the whole lung. This situation occurs at high altitude or during chronic 
parenchymal lung diseases, because of persistent global hypoxia and hypoxemia (110). In these 
disorders, sustained global HPV increases pulmonary vascular resistance, contributing to PH 
progression, that may be prevented by long term oxygen therapy. However, oxygen administration 
does not achieve a complete PH reversibility, demonstrating that the role of HPV in PH 
physiopathology is strictly related to presence of VSM remodeling. In fact, increase in VSM mass 
results in enhanced vasoconstriction due to HPV, with a proportionally more significant increase in 
vascular resistance. Furthermore, sustained vasoconstriction stimulates VSM hypertrophy, favoring 
advancement of vascular remodeling and disease progression (101). Pulmonary vascular endothelial 
dysfunction involves an imbalance of endothelial vasoactive mediator production. An increased 
endothelial expression of endothelin-1, the most potent vasoconstrictive mediator, is associated to a 
reduced expression of nitric oxide (NO) and prostacyclin synthases, with impairment of endothelium-
derived vascular relaxation mechanisms and overall increased vascular resistance. Change in 
endothelial-derived vascular tone regulation occurs as consequence of endothelial remodeling. In fact, 
in advanced COPD, impairment of NO release is correlated to the severity of hypoxemia and to the 
degree of pulmonary artery intimal layer thickening. Direct endothelial injury also affects endothelial 
mediator production. In smokers, cigarette smoke directly mediates endothelial injury, therefore 
endothelial dysfunction may also precede both COPD and PH onset (117, 120). 
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Mechanical factors Air trapping (alveolar hyperinflation) 
• Increased intra-alveolar volume 
(capillary stretching) 
• Increased intra-alveolar pressure 
(capillary compression) 
Increased blood viscosity 
• Secondary polycythemia 
Structural factors Vascular remodeling 
• Wall thickening (increased vascular 
stiffness and reduced lumen) 
• Vascular smooth muscle mass increase 
(smooth muscle hypertrophy, 
hyperplasia and neo-muscularization) 
Pulmonary vasculature re-distribution 
• Capillary destruction (emphysema) 
• Capillary obliteration (fibrosis) 
• Abnormal angiogenesis 
Biochemical/reflexive factors Sustained global hypoxic pulmonary 
vasoconstriction 
Endothelial dysfunction 
• Increased endothelin-1 production 
• Impaired nitric oxide and prostacyclin 
mediated vasorelaxation 
Table 4: Factors contributing to pulmonary hypertension physiopathology in chronic lung disorders (group 3). 
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Diagnosis and treatment 
 
In patients with chronic lung disease, the onset of PH may be difficult to detect clinically because 
symptoms do not differ from those of the respiratory disorder alone. Furthermore, concomitant left 
heart disease is frequent and may also contribute to the PH. All patients affected by chronic lung 
disease routinely undergo pulmonary function testing and arterial blood gas analysis: those patients 
showing clinical signs more severe than what expected according to results of these analyses should 
be suspected of PH. A disproportionally low lung diffusion capacity for carbon monoxide (DLCO) 
and pCO2 also suggest presence of PH in patients with chronic lung disease. All these patients must 
undergo echocardiographic screening evaluation for PH. Right heart catheterization should be 
performed to definitively confirm or rule out PH in cases of inconclusive echocardiography, 
especially when probability of PH is high, when patients are suitable candidates for surgical 
treatments (transplantation, lung volume reduction) or when other concomitant causes of PH (such 
as left heart disease) could be present, with the potential impact on PH therapeutic approach (74).  
So far, PH due to chronic lung disease has no specific therapy. Drugs that are currently administered 
for treating group 1 PAH, such as conventional calcium channel blockers vasodilators (CCBs), are 
not recommended in chronic lung disease because there is no evidence suggesting that they could 
improve pulmonary haemodynamics, clinical signs or prognosis. Furthermore, CCBs inhibit HPV, 
worsening ventilation/perfusion mismatch and gas exchange, being more deleterious than beneficial 
particularly in hypoxaemic patients (97, 121-125). The therapeutic approach should optimize the 
management of the underlying respiratory disorder. In COPD, long-term O2 administration 
represents the elective treatment and seems to prevent further progression of PH. However, 
normalization of mPAP is rarely obtained, because the increase in PVR due to pulmonary vascular 
remodeling persist after oxygen administration (126).  
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PULMONARY HYPERTENSION AND SEVERE EQUINE ASTHMA 
 
Pulmonary hypertension and related cardiovascular complications are reported in severe equine 
asthma. As human respiratory conditions associated with group 3 PH, severe equine asthma is 
characterized by alveolar hyperinflation, hypoxaemia and related HPV, all factors that could 
contribute to development of PH (50). However, disadvantages of available diagnostic techniques as 
well as unknown clinical significance has limited the interest in investigating PH in severe asthmatic 
horses. An overview about experimental case-control studies (51, 127-130) and case reports (131-
133) that focused on PH and related cardiovascular complications in severe asthmatic horses will be 
provided.   
 
PHYSIOPATHOLOGY AND CLINICAL PRESENTATION 
 
In horses, PH is diagnosed in presence of systolic and/or mean PA pressure values greater than 40 
mmHg and/or 35 mmHg respectively (133). Severe equine asthma is typically associated with 
recurrent reversible PH. A significant increase in mPAP occurs during exacerbation, leading to severe 
PH, with mPAP values that frequently reach 80 mmHg. However, disease remission or oxygen 
administration rapidly induce normalization of mPAP, even in horses with a long-term history of 
severe asthma. During remission, mPAP values of severe asthmatic horses, although within the 
normal range, remain significantly higher than those of healthy horses (51, 127). 
The main etiological factor contributing to PH onset during exacerbation is hypoxaemia. Although 
PH develops only in severe asthmatic horses, experimentally-induced hypoxaemia results in 
increased mPAP also in healthy horses, due to reflexive HPV (51). Furthermore, the severity of PH 
appears inversely correlated to PaO2,  evaluated with arterial blood gas analysis (129). The 
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determinant role of HPV is supported by the rapid decrease of mPAP values observed after oxygen 
administration (51).  
Nevertheless, oxygen administration is only partially efficacious in reversing PH of severe asthmatic 
horses and some horses in remission still show elevated mPAP even though PaO2 values are normal. 
Furthermore, in response to a similar PaO2 level drop, asthmatic horses but not healthy subjects 
develop PH, suggesting the involvement of other etiological factors that are still uninvestigated in 
severe equine asthma-associated PH (51, 129). Possible contributing factors include compression of 
capillaries due to positive intrapleural pressure and alveolar hyperinflation as well as vasospasm 
induce by inflammatory mediators (51, 129).   
 
CARDIOVASCULAR IMPLICATIONS 
 
Although severe equine asthma-associated PH is reversible, it could lead to onset of cardiovascular 
complications, particularly when the disease is advanced and the response to treatment is incomplete. 
The cardiovascular complications of PH described in severe asthmatic horses include cor pulmonale 
and dysrhythmias (atrial fibrillation).  
 
Cor pulmonale and cardiac remodeling 
 
The overall incidence of cor pulmonale appears to be low in severe equine asthma, compared to 
human chronic respiratory conditions. In severe equine asthma, cardiac overload is not persistent 
because PH is reversible, therefore it is likely that advanced stages as well as frequent exacerbations 
are required to induce significant cardiac remodeling. (127). However, it is not clear whether the low 
incidence reflects a real low occurrence or just a low sensitivity of the available diagnostic methods. 
In 1982, Dixon et al. systematically investigated presence of clinical right heart failure and post-
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mortem macroscopic findings suggestive of cor pulmonale, such as right ventricle (RV) hypertrophy 
and dilatation, in a group of severe asthmatic horses. Cardiac dilatation and clinical heart failure were 
not observed, while mild RV hypertrophy was detected in only few cases (127). More recently, two 
case reports described the occurrence of severe cor pulmonale associated with right-sided heart 
failure, showing clinical signs of mild distal limb edema and jugular vein distension, 
echocardiographic findings of severe tricuspid valve regurgitation and RV enlargement as well as 
marked increase of right ventricular pressure (85 mmHg) (131, 133). One case failed to respond to 
combined corticosteroid-bronchodilator therapy and was euthanized. At post mortem examination, 
lung tissue appeared extensively damaged with significant emphysema that was considered a more 
likely cause than right heart failure for the treatment unsuccess (131). The other case showed good 
response to the same treatment and complete regression of the related cardiac changes (133). 
Therefore, in severe asthmatic horses the presence of cor pulmonale do not represent a negative 
prognostic factor and adequate treatment of the primary respiratory condition may reverse not only 
PH but also related cardiac impairment.  
However, these observation does not rule out a significant clinical impact of recurrent PH and cor 
pulmonale (127). Recent evidence suggest that relative short periods of PH induce subclinical 
structural myocardial remodeling that persist during disease remission. These structural changes are 
probably underestimated because they could not be detected by conventional echocardiography or 
post-mortem macroscopic examination (129). Although subclinical, cardiac remodeling may 
significantly affect cardiac function during exercise as occurring in human athletes, where it is 
associated with increased risk ventricular dysrhythmias (134). As in human COPD, PH may early 
develop only during exercise in asthmatic horses, determining poor performance (128). Although 
mild increase in serum level of troponin physiologically occurs after exercise, it has been reported 
that asthmatic horses have abnormally increased troponin after slight exercise, reflecting possible 
myocardial stress due to exercise PH (129). 
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A description of the most significant findings suggestive of morphologic or functional cardiac 
abnormalities detected in severe asthmatic horses is provided below.  
 
Morphologic abnormalities 
Cardiac morphologic changes typical of cor pulmonale include RV hypertrophy, dilatation or both 
(85). During exacerbation, dilatation of right atrium and right ventricle as well as associated 
interventricular septum abnormalities may be detected by echocardiography, but are rarely 
appreciable at post mortem examination. Increase in right heart size may be associated with normal 
or reduced left ventricle size (127, 128, 132, 133). Morphologic septal abnormalities include 
flattening of the septal curvature, leftward deviation, hypokinesis or paradoxical motion (128, 129, 
132, 133). Increase in right ventricle overload may prevent physiological movements of the septum 
that normally contribute to the activity of the left ventricle (133). Other findings that suggest right 
heart dilatation are significant tricuspid or pulmonic valve regurgitations that could be detected as a 
right-sided systolic or left-sided diastolic murmurs respectively (132). Although significant murmurs 
may not be audible, regurgitations could be also assessed by color Doppler echocardiography (128, 
132, 133). Hypertrophy of the RV is more difficult to evaluate, since measurement of RV wall 
thickness is not enough sensitive, both at traditional echocardiography and at macroscopic post-
mortem examination (127, 128). In some cases, the visualization of a rounded heart apex at 
echocardiographic examination may suggest non-specific ventricular hypertrophy (133). Mild RV 
hypertrophy is more often detected at post-mortem examination, as a decreased weight ratio between 
left and right ventricles, indicating presence of heavier right ventricle (127, 131). A recent study 
detected a significant increase of RV wall thickness in severe asthmatic horses during remission, 
compared to healthy horses, suggesting that hypertrophy may persist also after normalization of 
mPAP values. The same study focused the attention on histological examination, a useful tool to 
assess presence of myocardial damage and cardiac remodeling induced by pressure overload and 
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particularly their persistence after PH regression. In one remission horse, endomyocardial biopsy 
revealed a focal interstitial neutrophilic infiltration. This finding could reflect a persistent 
inflammatory process induced by mechanical tension stress occurred during exacerbation (129). 
Morphologic abnormalities may be suggestive not only of cor pulmonale but also of PH. Dilatation 
of PA is considered as an indicator of PH and may be detected at traditional echocardiography as an 
increased PA diameter or more easily as a decreased ratio between aortic and PA diameters (128, 
132). Also at post- mortem examination, PA dilatation is more easily appreciated by calculating the 
ratio between aortic and PA circumferences. A decreased ratio suggests PA enlargement (127, 131).   
 
Functional abnormalities 
 
Although cardiac morphologic changes are not detected in all cases, presence of PH systemically 
induces altered RV function during exacerbation. During remission, as mPAP decreases, also 
normalization of cardiac function occurs. However, it is unknown whether subtle changes persist, 
contributing to exercise intolerance in severe asthmatic horses (128, 129).  
Most findings of altered RV functions are detected by echocardiography, particularly using color-
flowc and pulsed-wave Doppler evaluation or new developed techniques, such as tissue Doppler 
imaging (TDI) or 2D speckle tracking echocardiography (STE). Increase in PA pressure and volume 
may cause pulmonary insufficiency, altered RV systolic and diastolic function, as well as reduced 
RV contractility. Pulmonic valve insufficiency associated with PH is end-diastolic and characterized 
by high-velocity flow. In one case report, clinical signs of right heart failure were detected associated 
pulmonary insufficiency, indicating that this finding is typical of advanced disease stages (131). 
Altered RV systolic function is reflected by abnormal Doppler PA systolic trace, reflecting an altered 
RV ejection pattern that become more similar to that of the LV and decrease of systolic time intervals, 
including the acceleration time (AT), the RV-ejection time (ET), the AT:ET ratio, as a consequence 
of the increase in RV pressures and PH (132). Decrease and increase of early and late diastolic filling 
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velocities respectively suggest an impairment of the RV diastolic function, with prolonged isovolumic 
relaxation and pre-ejection period. Increased PA pressures and subclinical myocardial damage due to 
repeated hypoxaemia are considered as the most likely cause of altered relaxation (129). The longer 
pre-ejection period associated with a reduced segmental longitudinal strain also suggest an impaired 
RV contractility (129).  
Altered left ventricle (LV) function is also possible. A reduction of the contractility (shortening 
fraction) as well as of the estimated stroke volume may occur (128, 133). This is determined by a 
decreased left ventricular pre-load, due to the reduced pulmonary venous return associated with PH. 
However, an increase of the heart rate usually allows maintenance of a normal cardiac output (128).  
Interestingly, according to Decloedt et al., RV pressure and contractility of severe asthmatic horses 
in remission significantly differ from those of healthy horses, suggesting the presence of myocardial 
remodeling responsible for persistent RV subclinical altered function (129).  
 
Dysrhythmias (atrial fibrillation)  
 
In 2015, Hanka et al. described a case of paroxysmal atrial fibrillation in a severe asthmatic horse, 
occurring during exacerbation in association with evidence of reversible PH and cor pulmonale.  
Administration of combined corticosteroid and bronchodilator therapy resulted in normalization of 
both cardiac morphologic as well functional abnormalities and cardiac rhythm (133). The authors 
hypothesized that atrial enlargement due to cardiac morphologic abnormalities associated with PH 
may have been the cause of atrial fibrillation. However, dysrhythmias may also appear as a 
consequence of myocardial hypoxia, as a consequence of hypoxaemia and impaired gas exchanges 
related to the primary respiratory disorder (129). 
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DIAGNOSTIC ASSESSMENT 
 
Diagnostic assessment of PH and cor pulmonale in horses has several limitations that are related to 
the low sensitivity of available non-invasive techniques as well as to the invasiveness and 
expensiveness of the diagnostic gold standard (right heart catheterization). However, recent 
development of advanced echocardiographic-assisted techniques has improved diagnostic sensitivity, 
increasing the attention towards significance of sub-clinical structural and functional abnormalities 
that were previously undetectable (129).  
 
Right heart catheterization  
 
Right heart catheterization represents the gold standard to diagnose PH in equine as in human 
medicine. The procedure is invasive but is performed in standing non-sedated horses. In an area 
corresponding to the lower one-third of the jugular groove, a catheter is introduced through the skin, 
into the jugular vein and then advanced through the right atrium (RA), the RV and eventually about 
2 cm into the main PA trunk. The catheter is connected to a manometer placed approximately at the 
level of the shoulder point (level of the RA), then to a pressure transducer and a digital recording 
system (51). The technique allows estimation of systolic, diastolic and mean pressures of the RA, the 
RV and the PA. Normal ranges in the horse are reported in table 5 (131, 133, 135). During 
exacerbations, it is common to detect significant increase of mean RA pressure, systolic RV pressure, 
mean and systolic PA pressure (51, 129, 131, 133). Detection of increased RV pressures has been 
associated with clinical signs of right-sided heart failure (131, 133). Although invasive, right heart 
catheterization is the most sensitive technique, being able to detect significant differences in mPAP 
values between asthmatic horses in remission and healthy horses (51).  
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Pressure mmHg Right atrium Right ventricle Pulmonary artery 
Systolic - 40-60 32-38 
Diastolic - 10-14 15-22 
Mean 5-10 19-25 25-30 
Table 5: physiological ranges for right atrium (RA), right ventricle (RV) and pulmonary artery (PA) pressure in horses 
(135). 
 
Echocardiography 
 
Echocardiography is a non-invasive diagnostic method providing useful tools to investigate both 
presence of PH and cardiac abnormalities suggestive of cor pulmonale. Different echocardiographic 
techniques are available, allowing assessment of multiple parameters.  
 
Bi-dimensional echocardiography  
 
Bi-dimensional echocardiography requires a phased-array or micro-convex transducer, with a 
frequency of 2.5-3.5 mHz and a depth of 25-27 cm. Standard images are obtained both from the right 
and from the left side. Measurements should be collected at a standard moment of the breathing cycle, 
such as the end of inspiration, because of variations related to intrathoracic pressure changes (128).  
Measurements suggestive of both pulmonary hypertension and cor polmunale may be collected. 
 
o RV, LV, RA luminal diameters and LV/RV ratio 
These measurements estimate the size of the respective cardiac chambers. Increase in RV and 
RA diameter may suggest the presence of right heart (and particularly right ventricle) 
dilatation, as an indication of cor pulmonale. Decrease of LV diameter reflects reduction of 
LV size, due to RV overload and increased pressure, as an indirect indication of PH (128, 
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129, 132, 133). Measurements should be taken always at the end of the inspiration because 
of variations related to the breathing cycle. During inspiration, the ∆Ppl increases, facilitating 
the venous return to the right heart with increase in size of the RV. At the same time, the LF 
size reduces because an increase in the whole heart volume is prevented by the pericardium 
stiffness. These variations are negligible in a horses and in asthmatic horses during remission, 
however they become consistent during exacerbation of severe equine asthma, due to the 
significant increase of ∆Ppl (128).  
 
o RV free wall thickness 
An increase of RV wall thickness, assessed using the left side views, reflects RV hypertrophy, 
as indication of cor pulmonale (128). However, this parameter has a very low accuracy and 
sensitivity, being unable to detect mild RV hypertrophy, as often occur even in cases of 
consistent RV dysfunction (128, 131, 133). Although a significant increase in RV thickness 
is rarely detected during exacerbation, RV wall is significantly more thickened in asthmatic 
horses compared to healthy horses, also during remission, suggesting presence of persistent 
cardiac remodeling  (129). 
 
o Heart apex morphology 
An abnormal cardiac apex that appears round-shaped is consistent with ventricular 
hypertrophy. In those clinical cases suggestive of PH, a rounded apex may reflect RV 
hypertrophy and therefore suggest presence of cor pulmonale (133). 
 
o Interventricular septum morphology and motion 
Interventricular septum abnormalities include flattening, leftward deviation, hypokinesis and 
paradoxical septal motion. These abnormalities are related to the excessive RV afterload that 
impair the physiological synergic role between the septum and the left ventricle. Septal 
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abnormalities represent a frequent finding in severe asthmatic horses affected with cor 
pulmonale (128, 131-133).  
 
o PA, AO diameters and their ratio 
Increased PA diameter as well as an increase in the ratio between the PA and the AO 
diameters indicate dilatation of PA and are quite systematically detected during exacerbation 
(129). In severe cases, the PA diameter may become equal or greater than the AO diameter 
(131-133). Pulmonary artery dilatation represent the main echocardiographic finding 
allowing indirect, non-invasive, qualitative assessment of PH in horses (128).  
 
o Index of cardiac performances  
The most important indexes of global cardiac performances that could be assessed with bi-
dimensional echocardiography include the LV shortening fraction (and shortening area), the 
“estimated” stroke volume and the cardiac output. As mentioned above, during exacerbation 
a decrease in the LV shortening fraction reflects decreased LV contractility, while a reduced 
stroke volume is related to a decrease of LV preload associated with PH (128, 133) 
 
Color-flow Doppler 
 
Color-flow Doppler may be used to investigate presence of tricuspid or pulmonic valve regurgitation, 
that could appear as a consequence of right heart dilatation. In case of significant regurgitation, the 
subtended jet area may be measured as an indirect estimation of the PA pressure (128). Pulmonic 
valve insufficiency may be detected in case of severe cor polmunale and impending right-sided heart 
failure (131, 133). Presence of tricuspid regurgitation should be interpreted with caution. Mild or 
moderate tricuspid regurgitation often represents an incidental finding in older horses and is not 
associated with clinical signs of cardiac disease. Therefore, if mild-moderate tricuspid regurgitation 
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is found in severe asthmatic horses both during exacerbation and during remission, its significance as 
a marker of cor pulmonale is unlikely (128). Conversely, when moderate-severe tricuspid 
regurgitation is associated with consistent RV and RA enlargement and clinical signs of right-sided 
heart failure, it may be considered as an indication of ongoing cor pulmonale (133).   
 
Pulsed-Wave Doppler 
 
Pulsed-Wave Doppler is used to assess flow velocity and wave-form. Assessment of PA blood flow 
velocities, wave form and systolic time intervals, such as the AT, ET and the AT:ET ratio, gives 
information about the RV ejection pattern and related severity of PH, as shown in figure 1 (132). In 
case of moderate PH, a decrease of the AT may be observed, with subsequent steep appearance of 
the wave ascending phase. In case of severe PH, the AT may further decrease and a notch may appear 
in the middle of the descending phase, that looks relatively prolonged due to AT decrease (132). One 
should remind that Pulsed-Wave Doppler evaluation is accurate only if the beam is aligned with the 
blood flow. In case that a good alignment could not be achieved, the technique may fail in detecting 
typical findings suggestive of PH, although PH occurs (128). Furthermore, a decrease in systolic time 
intervals occur also in tachycardic horses, therefore more importance should be given to the AT:ET 
parameter, that is less influenced by heart rate (132).  
In case of significant tricuspid regurgitation, Pulse-Wave Doppler could be used to evaluate its 
maximum velocity and eventually to estimate the PA pressure, in absence of pulmonary outflow 
obstruction, using the same approach described by human PH diagnostic guidelines (74, 132). 
However, as for PA flow, the accuracy of estimation significantly depends on the alignment between 
the beam and the regurgitant flow (128). 
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Figura 1: Schematic representation of PA flow wave forms (132). In physiological conditions (Normal), the wave is 
symmetric, with similar acceleration time (AT) and deceleration phase. In case of moderate PH (Moderate), the AT 
significantly decreases: the wave loses its symmetric shape and the ascending phase becomes steep. In severe PH 
(Severe) the AT further decrease with an almost vertical ascending phase and a notch appear in the middle of the 
descending phase which appearance becomes biphasic. RVET=ET=right ventricular ejection time 
 
 
Novel techniques: tissue Doppler imaging (TDI) or 2D speckle tracking echocardiography (STE) 
 
Tissue Doppler imaging (TDI) and 2D speckle tracking echocardiography (STE) are recently 
developed techniques that allows a sensitive evaluation of the RV function. Their application in 
investigating PH and cor pulmonale in severe equine asthma gave interesting results, especially in 
comparing asthmatic and healthy horses.  
Also during remission, asthmatic horses may show greater left ventricular end-systolic eccentricity 
index, decreased longitudinal strain and longer RV pre-ejection period. All these findings suggest 
reduced RV contractility in asthmatic horses, probably reflecting the presence of structural subclinical 
cardiac remodeling.   
During exacerbation, employment of these techniques allows detecting functional abnormalities that 
could not be detected by traditional echocardiography. Severe asthmatic horses in exacerbation show 
prolonged pre-ejection period and isovolumic relaxation time, that are correlated with increase in PA 
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pressure and are suggestive of PH. Furthermore, presence of RV pressure overload may be indicated 
both by the presence of higher LV end-systolic eccentricity index, reflecting septal flattening, and by 
the presence of RV volume overload, reflected by a high LV end-diastolic eccentricity index (129). 
 
Endomyocardial biopsy and myocardial enzymes 
 
These methods are usually employed to investigate presence of myocardial damage. Myocardial 
enzyme (troponin) serum dosage has a low sensitivity, since myocardial damage may occur 
significantly, accompanied only by a slight increase of serum troponin (128). Endomyocardial biopsy 
is a recently described promising techniques allowing assessment of myocardial histological changes. 
Presence of structural remodeling may be subclinical but persistent during remission and whether it 
could have an impact on athletic performances of asthmatic horses still remains unknown (129).   
 
Post mortem examination 
 
Presence of PH and cor pulmonale may also be investigated at post mortem examination. One should 
measure the RV free wall thickness, the LV free wall thickness, the external circumferences of the 
AO and PA and the weight of RV and LF + septum (LV+S). The LV:RV free wall thickness ratio, 
the AO:PA circumference ratio as well as the LV+S:RV ratio should then be calculated (127, 131). 
 
o RV free wall thickness, LV free wall thickness 
The measurements must be collected about 20 minutes after death, as both ventricle are 
similarly fully contracted. RV wall thickness is obtained midway on a line joining the 
subauricular papillary muscle origin and the tricuspid valve. LV wall thickness was measured 
midway between the origins of the sub-auricular and sub-atrial papillary muscles. The LV:RV 
wall thickness ratio must be calculated. This parameter has low sensitivity and specificity. In 
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most cases, mild RV hypertrophy do not result in significant RV free wall thickening. 
Furthermore, great variations may occur in wall thickness according to the site of assessment 
and to the contraction state, also in healthy animals (127). 
 
o AO, PA external circumferences (and their ratio) 
External circumferences are evaluated at the vessel origin. An increase in PA external 
circumference as well as a decrease of AO:PA circumference ratio are often detected in severe 
asthmatic horses and reflect presence of PH (127, 131). In human, severe PH result also in PA 
muscle hypertrophy and endothelial arteriosclerotic-like changes, but usually these changes 
are not detectable in horses (127). 
 
o LV+S, RV weights (and their ratio) 
The most accurate assessment of RV hypertrophy (and related cor pulmonale) is by comparing 
the RV and LV +S weights, by calculating their ratio. The RV should be dissected separately 
free from the interventricular septum. The atria are removed from both ventricles. Usually, 
asthmatic horses have an increase in RV weight, resulting in decreased LV+S:RV ratio (127, 
131) 
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PART 2: RESEARCH PROJECT 
 
INTRODUCTION 
 
Severe equine asthma is a chronic, recurrent, non-infectious, inflammatory disorder affecting the 
equine lower respiratory tract, sharing pathophysiological similarities with human asthma (4). A 
multifactorial etiology has been proposed, involving a genetic predisposition to T2 helper 
lymphocyte-mediated immune response activation and exacerbating exposure to some environmental 
allergens, especially those found in moldy hay (6, 24).  
Clinical exacerbations are characterized by airway obstruction caused mainly by reversible 
bronchospasm but also by mucus and exudate accumulation, with increased pulmonary resistance, 
enhanced expiratory effort at rest and progressive alveolar hyperinflation (136, 137). Pulmonary 
neutrophilic inflammation, with a percentage of neutrophils at bronchoalveolar lavage fluid (BALF) 
cytology superior to 25% and systemic inflammation, with increased serum levels of haptoglobin are 
also typical features of the disease (37, 54). The inflammatory response induces lung tissue 
remodeling, involving both peripheral and central airways. Remodeled airways show increased 
smooth muscle mass, deposition of extracellular matrix and hyperplasia of mucous producing cells 
(7, 55). Airway remodeling worsens airflow obstruction, being responsible for its subclinical 
persistence also during remission (7, 10).  
Diffuse airway obstruction and alveolar hyperinflation increase dead space regions of high 
ventilation/perfusion (V/Q) ratios, due to pulmonary capillary mechanical compression. The resulting 
ventilation/perfusion (V/Q) mismatch impairs normal pulmonary gas exchanges, leading to 
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hypoxemia, clinically detectable as low arterial PO2. Magnitude of V/Q mismatch and hypoxemia 
correlates with severity of clinical signs during disease progression (50, 137).  
It is reported that chronic hypoxemia exacerbates sustained global hypoxic pulmonary 
vasoconstriction (HPV), increasing pulmonary vascular resistance and contributing to pulmonary 
hypertension (PH) onset and progression (110).  
Pulmonary hypertension and reversible cor pulmonale are reported as clinical complications during 
exacerbation of severe equine asthma. At echocardiographic examination, severe asthmatic horses 
may show increased pulmonary artery (PA) diameter, enlarged right ventricle and atrium with high-
velocity end-diastolic pulmonary insufficiency, rounded heart apex, hypokinetic and flattened 
interventricular septum, reduced left ventricle size and contractility (128, 131, 133). Advanced 
techniques such as tissue Doppler and speckle tracking echocardiography may detect altered right 
ventricular function and paroxysmal atrial fibrillation may appear as further complications (129, 133). 
Abnormal increased PA pressures may be measured by invasive right heart catheterization and 
pressure values are inversely correlated with arterial oxygen tension, suggesting a significant role of 
HPV (51, 129). However, PH is only partially reversed by oxygen administration and asthmatic 
horses have a significantly higher PA pressure compared to healthy horses, also during disease 
remission (51, 129). Therefore, other factors likely contribute to PH onset in asthmatic horses but 
they are not yet investigated.  
In experimental rodent models, chronic hypoxia and hypoxemia induce pulmonary vascular 
remodeling that mainly involves small pulmonary arteries (116, 138-140). Remodeled muscular 
arteries show increased vascular smooth muscle (VSM) mass because of intimal muscularization and 
medial smooth muscle hypertrophy (138, 139). Muscularization of distal arterioles also occurs (116, 
140). Pulmonary vascular remodeling may also develop in chronic inflammatory respiratory 
disorders. In human chronic obstructive pulmonary disease (COPD), remodeling of pulmonary 
arteries is well documented while it is poorly investigated in human asthma (117). Increased 
eosinophilic adventitial infiltration was detected in muscular pulmonary arteries of human patients 
52 
 
dead because of acute asthma attack (141). Furthermore, studies on asthma mouse models showed 
that allergic airway inflammation can induce pulmonary vessel remodeling, with increased VSM 
mass that persist during short-term disease remission (142-144). The overall increase in VSM mass 
results in artery wall thickening, lumen narrowing and vasoreactivity enhancement, with subsequent 
pulmonary vascular resistance augmentation (139). In human COPD, pulmonary artery remodeling 
is recognized as a determining factor in the onset of pulmonary hypertension and cor pulmonale, that 
represent typical end-stage disease complications (101).  
We therefore postulated that hypoxemia and chronic airway inflammation occurring in severe equine 
asthma may induce remodeling of small pulmonary arteries, similarly to what is reported in human 
chronic lung diseases. If present, pulmonary artery remodeling could then contribute to both PH onset 
during clinical exacerbation of the disease and persistence of higher PA pressure values during the 
disease remission. According to our hypothesis, the present study had the following objectives: to 1) 
determine the presence and anatomical location of pulmonary artery remodeling in severe equine 
asthma, 2) assess whether differences are detectable between remission and/or exacerbation state of 
the disease, 3) investigate the remodeling pattern and whether an increase of VSM mass is present 
and, 3) assess remodeling reversibility after a long-term asthma treatment. 
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STUDY DESIGN 
 
A blinded histomorphometric assessment was conducted in three phases, i.e. a preliminary post-
mortem case-control study, an in vivo case-control study and a prospective randomized in vivo clinical 
trial.  
The preliminary post-mortem case-control study aimed to determine presence of pulmonary artery 
remodeling, to evaluate its anatomical location in the lung, to assess differences between remission 
and exacerbation of the disease. The study was performed on lung histological samples collected 
post-mortem from 12 asthmatic horses and 6 age-matched controls. Among asthmatic horses, 6 were 
in exacerbation (exposition to the exacerbating antigen) and 6 were in remission (short-term antigen 
avoidance) at the moment of euthanasia. Pulmonary artery wall area was measured by 
histomorphometry, as an estimation of the degree of wall thickening. Measurements were compared 
between asthmatic horses and controls for the whole lung and for different lung regions. A 
comparison between asthmatic horses in remission and exacerbation was also performed. 
The in vivo case-control study was aimed to confirm post-mortem results and to characterize the 
vascular smooth mass involvement in the remodeling process. Peripheral lung biopsies were collected 
via thoracoscopy from the caudodorsal lung of 6 asthmatic horses in remission and 5 age-matched 
controls. Pulmonary artery wall area was measured similarly to the preliminary post-mortem study 
on histological samples. Furthermore, the intimal and medial areas were evaluated, to assess presence 
of specific intimal and/or medial thickening. The VSM mass and the extracellular matrix (ECM) were 
quantified by a point counting technique on sections immunostained for smooth muscle specific α-
actin (α-SMA). Measurements were compared between asthmatic horses and controls. 
The in vivo prospective randomized clinical trial was performed on 11 asthmatic horses to assess 
reversibility of wall and VSM changes after long-term asthma treatment. As a baseline, lung biopsies 
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were collected during clinical exacerbation. Pulmonary artery wall area and VSM mass were 
quantified by histomorphometry, similarly to the in vivo case control study. Then, horses were 
randomly divided into 2 groups and treated for 12 months with two different protocols. Five horses 
were treated only with the antigen avoidance strategy for the whole experimental period. Six horses 
were treated with the only administration of inhaled corticosteroids for 6 months and then with a 
combination of corticosteroid inhalation and antigen avoidance for the remaining 6 months. After 
treatment, peripheral lung biopsy collection and histomorphometry were repeated as a follow-up 
evaluation. For each horse and each group, a comparison between the wall area and VSM mass 
amounts at baseline and follow-up was performed. 
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MATERIALS AND METHODS 
 
Animals 
 
For the post-mortem study, horses were selected from the caseload available in our equine respiratory 
tissue biobank (http://www.btre.ca). For the in vivo studies, horses belonged to the experimental court 
of a larger project aiming to assess lung tissue remodeling and its reversibility in severe equine asthma 
(7, 8).  All the asthmatic horses had a well-documented 3–10-year history of largely reversible airway 
obstruction and inflammation. Clinical remission of the disease was experimentally obtained by 
keeping asthmatic horses on pasture for 2-4 months before recruitment for the study. Clinical 
exacerbation was experimentally induced by stabling asthmatic horses indoor and exposing them to 
moldy hay. Control horses were selected according to absence of previous respiratory disease in their 
history and age-matched to asthmatic horses. Animal manipulation and euthanasia were performed 
in accordance with the guidelines of the Canadian Council for Animal Care. 
 
Treatments 
 
The antigen avoidance strategy consisted in keeping horses on pasture during the summer months, 
and in a paddock during the winter. A pelleted diet was administered as supplementation to cover 
nutritional requirements while avoiding exposition to exacerbating allergens. Corticosteroid 
treatment consisted in inhaled fluticasone propionate (Flovent HFA; GlaxoSmithKline, Montreal, 
PQ, Canada) administered at the dose of 2-3 mg twice a day. 
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Lung function and BALF cytology 
 
Lung function and BALF cytology were assessed before euthanasia or lung biopsy collection, as 
previously described (24, 145). Briefly, pulmonary resistance and elastance were calculated from 
flow rates obtained from a heated pneumotachograph attached to a mask and transpulmonary pressure 
(∆Ppl) was derived from an esophageal catheter. For BALF collection, a 2.50 m endoscope (Olympus 
Medical Systems Corp., Tokyo, Japan) was used to instill and recover two boluses of 250-ml isotonic 
saline in the main bronchi. Cytospins were obtained and stained with Wright-Giemsa.  
 
Lung sampling techniques 
 
In vivo sampling 
Lung biopsy was performed via thoracoscopy in standing sedated horses and peripheral lung tissue 
(8-12 cm3) was obtained from the caudodorsal region of the lung as previously described (146).  
Post-mortem sampling 
After euthanasia and blood removal by gravity after carotid incision, the whole lungs were removed 
from the thoracic cavity. Lung samples of 8-12 cm3 were collected from different regions of the left 
lung. Samples were named cranio-caudally from “A” to “D”. A further sample named “E” was 
collected from the region corresponding to the biopsy site during thoracoscopy procedures. Specific 
sites of collection are shown in figure 1. 
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Figure 1: lung sites of post-mortem sampling. Sample “A” was collected from the lung apex. Sample “B” 
was collected at the emergence of the main bronchus. Sample “C” was collected from the center of the main 
lung lobe. Sample “D” was collected from the caudodorsal part of the main lung lobe. Sample “E” was 
collected from the peripheral caudodorsal part of the main lung lobe and corresponds to the specific biopsy 
site during thoracoscopy.  
 
Processing and staining 
Lung samples were fixed for 24 hours in 4% formaldehyde, embedded in paraffin, cut, placed on 
glass slides and stained. Post-mortem samples were stained for histology with hematoxylin eosin 
saffron. In vivo samples were stained for histology with Movat Russel Pentachrome. This staining 
highlights the internal elastic lamina, allowing differentiation between intimal and medial layers 
within the artery wall. In vivo samples were also immunostained for α-SMA, as previously described 
(45).  
 
 
 
58 
 
Histomorphometry 
 
Histology 
Post mortem and in vivo histological sections were scanned and digitalized at 40X magnification as 
TIFF images with PanOptic software version 1.4.3; morphometric measurements were collected on 
TIFF images using Image-Pro Plus software version 1.4g (MediaCybernetics, Carlsbad, CA). For 
each horse, all the artery sections having enough preserved integrity to allow clear distinction between 
the artery wall and the lumen, were evaluated. Both linear (1D) and bidimensional (2D) parameters 
were measured or derived, as previously reported for human pulmonary vascular histomorphometry 
(147-149). In brief, “1D (µm) measured parameters” included length of external artery diameter (ED), 
greatest longitudinal axis (GLA), external perimeter (EP), internal perimeter (IP) and lumen perimeter 
(LP). In horses, muscular pulmonary arteries have a minimal ED of 40 µm therefore, arteries with 
lower ED length were excluded (150). 2D measurements (µm2) included the total area (TA), the 
internal area (IA) and the lumen area (LA). Definition and collection methods of 1D and 2D 
“measured parameters” are summarized in table 1 and figure 2 respectively. The IP and the IA were 
measured on Movat Russell Pentachrome stained sections (in vivo case-control study), only if the 
artery internal elastic lamina appeared well defined in the whole artery. “Derived parameters” 
included the wall area (µm2), the intimal area (µm2) and the medial area (µm2), the ratio between 
greatest longitudinal axis and external diameter (GLA/ED ratio) and the narrowing index. “Derived 
parameters” were calculated from “measured parameters”, according to definitions resumed in table 
2 (Office Excel software v. 2016; Microsoft Corporation, Redmond, USA). The intimal area and the 
medial area were obtained only if IA measurement was available. To allow comparison among data 
of different sized-artery sections, these measurements were also expressed as percentages of the total 
area (wall area %, intimal area % and medial area %). Longitudinal sections of vessels (GLA/ED 
ratio > 3) were excluded, as previously suggested (149). 
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1D measured parameters (µm) 
External artery diameter (ED) Widest distance between external elastic laminas, 
perpendicular to the greatest longitudinal axis 
Great longitudinal axis (GLA) Longest distance between external elastic laminas 
External perimeter (EP) Outline of the external elastic lamina 
Internal perimeter (IP)* Outline of the internal elastic lamina 
Lumen perimeter (LP) Outline of the inner aspect of the intima 
2D measured parameters (µm2) 
Total area (TA) Area encompassed by the external perimeter 
Internal area (IA)* Area encompassed by the internal perimeter 
Lumen area (LA) Area encompassed by the lumen perimeter 
Table 6: 1D and 2D “measured parameters”. These parameters were already defined for pulmonary vascular 
histomorphometric studies in human COPD (149). Those parameters marked with (*) were assessed only on 
sections stained with Movat Russel Pentachrome (in vivo case-control study). 
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Figure 2: histomorphometric 1D and 2D measured parameters. Muscular pulmonary artery and annexed 
bronchus histological sections were scanned at 40X and stained with hematoxylin eosin saffron (for the post-
mortem study) or Movat Russel Pentachrome (for the in vivo study, as in this picture). Elastic fibers are stained 
black with Movat Russel Pentachrome, outlining the internal elastic lamina and allowing differentiation 
between intimal and medial layers. GLA (red outline) =great longitudinal axis; ED (green outline) =external 
diameter; EP (yellow outline) =external perimeter; IP* (blue outline) =internal perimeter; LP (pink outline) 
=lumen perimeter; TA (within yellow outline) =total area; IA* (within blue outline) =internal area; LA (within 
pink outline )=lumen area.   
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Derived parameters 
Wall area (µm2) Area included between the external perimeter and the lumen perimeter, 
calculated as difference between total measured area and lumen area 
Medial area (µm2)* Area included between the external perimeter and the internal perimeter, 
calculated as difference between total measured area and internal area 
Intimal area (µm2)* Area included between the internal perimeter and the lumen perimeter, 
calculated as difference between internal area and lumen area 
GLA/ED ratio Ratio between greatest longitudinal axis and external artery diameter 
Narrowing index Index of artery collapse estimated as the ratio between the total measured 
area (TA) and the theoretical area. The theoretical area represents the area 
of the fully distended artery obtained from a theoretical diameter 
calculated as follows: EP/π 
Table 7: 2D derived parameters. These parameters were defined for pulmonary vascular histomorphometric 
studies in human COPD (149). Those parameters marked with (*) were assessed only on sections stained with 
Movat Russel Pentachrome (in vivo case-control study). Narrowing index and GLA/ED ratio were used to 
assess differences due to histological processing and cut sections respectively. 
 
 
Immunohistochemistry 
Immunostained muscular pulmonary arteries were scanned at 40X magnification and digitalized as 
SVS images with PanOptic software version 1.4.3. Histomorphometry was then performed on the 
SVS images using the NewCAST software version 4.5.1.324 (Visiopharm Integrator System, 
Hoersholm, Denmark). The total vessel area (µm2) and the α-SMA positive and negative wall area 
(µm2) were estimated with a counting point technique. Briefly, on each uploaded SVS digital image, 
every visible pulmonary artery section was delimited as a region of interest (ROI), using the “ROI 
drawing” function. The parameters counted were the sum of the points falling on vessel lumen and 
wall surfaces (∑pvessel), the sum of the points falling on α-SMA positive wall surface (∑pα-SMA+) and 
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the sum of the points falling on α-SMA negative wall surface (∑pα-SMA-). A grid of 576 crosses per 
screen was applied since this point density provided a total count of at least 400 points for every 
counted parameter in each horse, an essential condition to ensure a reliable individual estimation 
(figure 3). The total vessel area, the α-SMA positive wall area and the α-SMA negative wall area 
were estimated by multiplying the ∑pvessel, ∑pα-SMA+ or ∑pα-SMA- respectively per the surface 
subtended to a single point (117,22 µm2). The total vessel area reflects the overall surface occupied 
by the artery section (both lumen and wall surface), while the α-SMA positive wall area and the α-
SMA negative area reflect respectively the VSM and ECM mass within the artery wall. Both α-SMA 
positive and negative wall areas were then expressed as a percentage of the total vessel area (α-SMA+ 
area %, α-SMA- area %), to allow comparison among data of different sized-artery sections.  
 
 
Figure 3: immunostaining for α-SMA and point counting analysis. Vascular smooth muscle (VSM) stained 
pink-red with immunostaining for α-SMA, while ECM did not stain. An example of ROI analysis with the 
point counting technique is provided. A grid of 576 crosses/screen was applied. Crosses falling on pink-red 
artery wall points (red circle) were counted as α-SMA+ (representative of VSM). Crosses falling on uncolored 
artery wall points (yellow circle) were counted as α-SMA- (representative of ECM). 
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Statistical analysis 
 
Age, lung mechanics and BALF cytology 
For the post-mortem study, mean values and standard deviations of age, lung function measurements 
(∆Ppl, resistance, elastance) and BALF neutrophil % were calculated for each group (controls, 
remission and exacerbation) (Office Excel software v. 2016; Microsoft Corp., Redmond, USA). 
Presence of significant differences among groups was investigated using the one-way Analysis of 
Variance (ANOVA) with Bonferroni’s multiple comparison post-hoc test (GraphPad Prism software 
version 6; Graphpad software Inc., California, USA). Level of statistical significance was set at 
p<0.05. For the in vivo studies, details of statistical analysis are already described elsewhere (7, 8). 
 
Histomorphometry 
For the post-mortem and in vivo case-controls studies, mean and standard deviation (SD) of 
morphometric measurements were calculated for each horse (individual means). Case-control 
comparisons were performed using individual means. A two-tailed t Student test with Welch’s 
correction was used in comparing groups for narrowing index and GLA/ED ratio, to assess 
differences related to histological processing. A one-tailed t Student test with Welch’s correction was 
used to compare the two groups for the wall area %, intimal area %, medial area %, α-SMA+ area %, 
since greater individual means were expected in asthmatic horses. To compare asthmatic horses in 
remission and asthmatic horses in exacerbation a two-tailed t Student test with Welch’s correction 
was used. For the in vivo prospective clinical trial, mean and standard deviation (ds) of morphometric 
measurements were calculated for each horse at baseline (individual means before treatment) and at 
the follow-up (individual means after treatment). A two-tailed paired t Student test was used to 
compare narrowing index and GLA/ED ratio while a one-tailed paired t Student test was used to 
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compare wall area % and α-SMA+ area % of each treatment group between baseline and follow-up, 
since lower individual means were expected at the follow-up. Means and SD were calculated with 
Office Excel software v. 2016 (Microsoft Corporation, Redmond, USA) and statistical tests were 
performed with GraphPad Prism software v. 6 (Graphpad software Inc., California, USA). The level 
of statistical significance was set at p < 0.05.  
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RESULTS 
 
Preliminary post-mortem study 
 
Age, lung mechanics and BALF cytology 
Age, lung function measurements and neutrophil % in BALF are reported in table 3. All groups are 
age-matched, as shown in figure 4a. A significant increase of cytological neutrophil % in BALF is 
associated with asthma exacerbation, while no difference was detectable between controls and 
asthmatic horses in remission (figure 4b). Similarly, lung function was significantly deteriorated by 
disease exacerbation, while during remission values were comparable to those of controls (figure 4c).   
 
Group Age 
(years) 
Lung mechanics BALF 
Neutrophils (%) ∆Ppl 
(cmH2O) 
Resistance 
(cmH2O/L/s) 
Elastance 
(cmH20/L) 
Controls 24 ± 5 5.261 
± 3.448 
0.6203 
± 0.2333 
0.6558 
± 0.1576 
1.19 
± 1.28 
Remission 25 ± 5 11.270 
± 3.273 
0.8335 
± 0.2965 
0.6633 
± 0.2851 
10.75 
± 10.28 
Exacerbation 25 ± 5 37.550 
± 16.060 
2.3480 
± 0.5611 
2.0250 
± 1.3060 
30.90 
± 14.55 
Table 3: means and standard deviations of age, lung function measurements and BALF neutrophils % 
(post-mortem study). ∆Ppl = transpulmonary pressure. 
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Fig. 4a: age (post-mortem study).
Controls, remission and exacerbation
horses did not significantly differ in age
(p=0.853).
Fig. 4b: neutrophil % at BALF
cytology (post-mortem study).
Neutrophil % was significantly higher in
exacerbation compared to both controls
(p<0.001) and remission (p<0.01). Fig. 4c: Lung mechanics
(post-mortem study).
During exacerbation, asthmatic horses
showed deterioration of lung function,
compared to controls and remission
horses, with significant increase of
transpulmonary  pressure (Ppl;
p<0.001), resistance (p<0.001) and
elastance (p<0.05). No significant
differences were detected between
remission horses and controls.
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Histomorphometry 
The average number of histological pulmonary arteries assessed per horse was 42±14 in the asthmatic 
group (45±13 for the remission group; 38±14 for the exacerbation group) and 37±12 in the control 
group. Means and standard deviations of each morphometric parameter are resumed in table 4. The 
two groups did not significantly differ in respect to GLA/ED ratio (p=0.07), but differences were 
detected in the narrowing index that was significantly higher in the asthmatic group (p=0.0005) than 
in controls (figure 5a). Asthmatic horses had significantly increased % of wall area when compared 
to controls (p=0.03) and artery remodeling was similar in severe asthmatic horses either in 
exacerbation and in remission (p=0.70). These changes were due to significant artery wall thickening 
in sample A and D that respectively correspond to the apex (p=0.003) and caudodorsal lung fields 
(p=0.03). Significant remodeling was also detected in sample E, the specific region sampled via 
thoracoscopy in the subsequent in vivo studies (p=0.02). 
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Group GLA/ED ratio Narrowing index Wall area (%) 
Controls 1.80 ±0.07 0.58 ±0.04 38.31 ±5.70 
Sample A 35.39±7.06 
Sample B 40.22±7.50 
Sample C 39.41±11.51 
Sample D 38.13±10.18 
Sample E 42.03±7.50 
Asthma 1.71 ±0.12 0.70 ±0.05 49.09 ±12.52 
 Remission 50.58±14.10 
Exacerbation 47.60±11.87 
Sample A 50.66±13.16 
Sample B 47.23±13.16 
 Sample C 46.19±11.44 
Sample D 50.56±15.01 
Sample E 55.55±14.84 
Table 4: means and standard deviations of morphometric parameters (post-mortem case-control 
study). GLA/ED ratio=ratio between the great longitudinal axis and the external diameter. 
 
69 
 
Controls Asthma
1.4
1.6
1.8
2.0
p=0.07
G
L
A
/E
D
ra
ti
o
Controls Asthma
0.6
0.7
0.8
***p=0.0005
N
a
rr
o
w
in
g
 i
n
d
e
x
Controls Asthma
20
40
60
80 *p=0.01
W
a
ll
 A
re
a
 (
%
)
Remission Exacerbation
20
40
60
80
p=0.70
W
a
ll
 A
re
a
 (
%
)
Figure 5a: GLA/ED ratio and narrowing index comparison (post mortem case-control
study). Asthmatic horses and controls did not significantly differ in respect to histological cut
section (GLA/ED ratio) but a significantly higher narrowing index was detected in asthmatic
horses, indicating different post-mortem lung tissue reaction to histological processation.
Figure 5b: histological morphometric remodeling comparison (post mortem case-control
study). Asthmatic horses showed significant wall thickening (increased % of wall area), compared
to controls. Remodeling did not significantly differ between asthmatic horses in remission and in
exacerbation.
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Figure 6: histological morphometric remodeling comparison of samples from different lung
regions (post mortem case-control study). Asthmatic horses showed significant remodeling
compared to controls in the apex (sample A) and in the caudodorsal lung field (sample D).
Significant pulmonary artery remodeling was also shown in sample E that corresponds to the specific
site of lung biopsy collected in the in vivo study. Remodeling was not detectable in the main lung
lobe (sample B and C).
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In vivo studies 
 
Age, lung mechanics and BALF cytology 
All details have been reported elsewhere (7, 8). 
 
Histomorphometry 
In vivo case-control study 
The average number of histological pulmonary arteries assessed per horse was 19±14 in the asthmatic 
group and 19±10 in the control group. The average number of immunostained pulmonary arteries 
assessed per horse was 19±11 in the asthmatic group and 22±8 in the control group. Means and 
standard deviations of each morphometric parameter are provided in table 5. The two groups did not 
significantly differ in respect to GLA/ED ratio (p=0.19) and to the narrowing index (p=0.12), 
(figure 7a). Asthmatic horses had significantly increased % of wall area when compared to controls 
(p=0.03). However, it was not associated with a specific increase in % of medial area (p=0.44) or % 
of intimal area (p=0.46) (figure 7b). The immunohistochemistry revealed that in asthmatic horses, the 
increase in % of wall area corresponded to a significant increase in the % of VSM mass (α-SMA+ 
area %, p=0.04) but not in ECM (α-SMA- area, p=0.21), as shown in figure 7c.  
Group GLA/ED 
ratio 
Narrowing 
index 
Wall area 
(%) 
Medial area 
(%) 
Intimal area 
(%) 
α-SMA+ area 
(%) 
α-SMA- area 
(%) 
Controls 1.77 ±0.11 0.65 ±0.04 67.26 ±6.67 51.75 ±5.95 21.97 ±3.17 41.07 ±6.22 39.52 ±10.29 
Asthma 1.66 ±0.14 0.70 ±0.04 74.51 ±2.78 52.21 ±4.60 22.13 ±3.33 47.17 ±3.17 35.06 ±5.30 
Table 5: means and standard deviations of morphometric parameters (in vivo case-control study). 
GLA/ED ratio=ratio between the great longitudinal axis and the external diameter; α-SMA+ area (%) = 
vascular smooth muscle (VSM) %; α-SMA- area (%)= extracellular matrix (ECM) %. 
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Figure 7a: GLA/ED ratio and narrowing index comparison (in vivo case-control
study). Asthmatic horses and controls did not significantly differ in respect to histological
cut section (GLA/ED ratio) and degree of artery collapse due to histological processation
(narrowing index).
Figure 7b: histological morphometric remodeling comparison (in vivo case-control
study). Asthmatic horses showed significant wall thickening (increased % of wall area),
compared to controls. However, this did not correspond to specific medial and/or intimal
thickening (% of medial and/or intimal area).
Figure 7c: immunohistochemical morphometric remodeling comparison (in vivo case-control
study). Asthmatic horses showed significant increase in vascular smooth muscle (VSM) mass (increased
% of -SMA+ area), compared to controls. No signifcant increase in extracellular ,matrix (ECM) mass
(% of -SMA- area) was observed.
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In vivo prospective clinical trial 
At the baseline, 18±10 immunostained and 12±10 histological arteries were measured per horse in 
the group treated only with antigen avoidance; 12±7 immunostained and 8±3 histological artery 
sections were measured per horse in the group treated with corticosteroids (alone for 6 months, and 
combined with antigen avoidance for 6 months). At the follow-up, these numbers were 13±6 
immunostained sections, 25±14 histological sections in the antigen avoidance group and 16±9 
immunostained sections, 21±9 histological sections in the corticosteroid treated group respectively. 
One horse of the antigen avoidance group was not considered for the statistical analysis of the VSM 
quantification because at the baseline only one immunostained artery was measurable. Means and 
standard deviations of GLA/ED ratio, narrowing index, wall area (wall area %) and VSM mass (α-
SMA+ area %) in the two groups at baseline and follow-up are resumed in table 6. The GLA/ED ratio 
did not differ between baseline and follow-up in both groups (p=0.46 and p=0.93), as shown in the 
figure 8a. The narrowing index was almost significantly reduced at the follow-up in the corticosteroid 
treated group (p=0.06) but was unaffected in the antigen avoidance group (p=0.35), as shown in 
figure 8b. Long-term treatment induced significant reduction of the wall area occurs both in antigen 
avoidance group (p=0.008) and in the corticosteroid treated group (p=0.04), as shown in figure 9a. 
The antigen avoidance strategy was associated with an almost significant VSM % reduction (p=0.05), 
while this does not happen with the steroid administration strategy (p=0.27) (figure 9b). 
Time Group Narrowing 
index 
GLA/ED 
ratio 
Wall area 
(%) 
α-SMA+ area 
(%) 
Baseline Antigen avoidance 0.69±0.08 1.60±0.23 74.79±17.56 49.26±5.59 
Corticosteroids 0.68±0.03 1.79±0.10 69.73±10.17 49.83±7.65 
Follow-up Antigen avoidance 0.63±0.10 1.71±0.13 56.97±14.81 39.64±4.03 
Corticosteroids 0.61±0.06 1.79±0.15 53.42±14.81 45.35±15.00 
Table 6: means and standard deviations of morphometric parameters (in vivo clinical trial). 
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Figure 8a: GLA/ED ratio comparison (in vivo clinical trial). Both treatment group did
not significantly differ in respect to GLA/ED ratio, showing similar histological cut section
at baseline and follow-up.
Figure 8b: narrowing index comparison (in vivo clinical trial). The antigen
avoidance group did not significantly differ in respect to narrowing index between
baseline and follow-up. Conversely, in the corticosteroid treated group the narrowing
index was almost significantly reduced at the follow-up.
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Figure 9a: histological morphometric remodeling comparison (in vivo clinical trial).
In both groups, a significant reduction of the pulmonary artery wall area was observed at the
follow- up. The reversibility of the wall area remodeling is more uniformely  achieved with the
antigen avoidance strategy than with the administration of corticosteroids.
Figure 9b: immunohistochemical morphometric remodeling comparison (in vivo
clinical trial). An almost significant and uniform reduction of the VSM  was observed at
the follow-up in the antigen avoidance group but not in the corticosteroid treated group.
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Summary of in vivo results 
The figures 10a and 10b graphically summarize the results of the in vivo studies, including both the 
case-control study and the clinical trial.  
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Figure 10a: summary of in vivo histological morphometric remodeling results. Asthmatic horses showed
higher mean pulmonary artery wall area compared to controls, that was not modified by the disease status (remission
or exacerbation). A normalization of the mean pulmonary artery wall area was observed after 11 month of treatment
both with corticosteroids and with antigen avoidance.
Figure 10b: summary of in vivo immunohistochemical morphometric remodeling results. Asthmatic horses
showed higher  pulmonary artery VSM compared to controls, that was not modified by the disease status (remission
or exacerbation). A normalization of the mean pulmonary artery wall area was observed after 11 month of treatment
with antigen avoidance but not with corticosteroids (less uniform response to treatment).
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DISCUSSION 
 
The present study investigated and characterized pulmonary artery remodeling in severe equine 
asthma using histomorphometry. Remodeling reversibility during short term disease remission and 
after long term treatment was also assessed, to evaluate whether structural alterations could contribute 
to the persistent increase of pulmonary artery pressure previously demonstrated during remission state 
of the disease (51). Both post-mortem and in vivo histomorphometry showed significant pulmonary 
artery wall thickening (increase in pulmonary artery wall area) in asthmatic horses compared to 
controls, that did not differ between exacerbation and remission. Furthermore, at post mortem, 
histomorphometric analysis revealed that pulmonary arteries of asthmatic horses appeared 
significantly less collapsed (higher narrowing index) than those of control horses. This difference was 
not remarkable in thoracoscopic lung biopsies, where both group showed similar low degree of 
pulmonary artery collapse (high narrowing index). Post mortem sampling of multiple lung regions 
showed that pulmonary artery wall thickening affected lung apex and caudodorsal lung fields, 
including the specific region sampled by in vivo thoracoscopy. In asthmatic horses, pulmonary artery 
wall thickening was due to a significant increase in VSM but not to an increase in ECM in then whole 
artery wall, as shown by the in vivo study. During exacerbation induced by antigen exposure, 
asthmatic horses showed significant airway neutrophilic inflammation (increase in neutrophil % at 
BALF cytology) and airway obstruction (significant lung function deterioration) compared to 
controls. Short term antigen avoidance alone (2-4 months of disease remission) significantly reduced 
BALF neutrophil count and ameliorated lung function but did not affect pulmonary artery remodeling 
changes in asthmatic horses. However, reversibility of pulmonary artery wall area and VSM was 
uniformly achieved after long term antigen avoidance (12 months). Combination of long term inhaled 
corticosteroids (12 months) and medium-term antigen avoidance (6 months) had less efficacy, 
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because pulmonary artery wall thickening and VSM were less uniformly reversed compared to long 
term antigen avoidance alone. 
To the best of our knowledge, this is the first study that investigated pulmonary vascular remodeling 
in severe equine asthma. Investigation of pulmonary vascular remodeling also lack in human chronic 
asthma, with studies limited to experimental rodent models (142-144). Pulmonary artery remodeling 
had not been previously investigated in asthma, likely because the prevalence of pulmonary 
hypertension is unknown and unlikely to be clinically important at rest. However, would pulmonary 
hypertension may develop during effort, contributing to exercise intolerance in asthmatic patients and 
horses, it could then have important consequences to the quality of life of affected patients. Severe 
asthmatic patients rarely undergoing lung transplantation or peripheral lung biopsy procedure due to 
ethical limitations, limiting availability of lung histological samples may have also contributed to 
overlooking pulmonary arterial wall remodeling in severe asthma. Therefore, studying horses with 
severe equine asthma, as condition sharing many clinical and remodeling features with human 
asthma, may provide useful results for both species (4). A quantitative histomorphometric approach 
was extensively adopted to assess pulmonary vascular remodeling in human COPD (111, 120, 149, 
151). Nevertheless, this is the first study that used a quantitative histomorphometric approach to 
assess pulmonary vascular remodeling in horses. Previous studies demonstrated pulmonary artery 
and vein remodeling in equine exercise-induced pulmonary hemorrhage (EIPH), using qualitative 
and semi-quantitative histopathology (152, 153).The present study showed that pulmonary artery wall 
area of asthmatic horses was about 7% and 12% higher than that of controls, in vivo and post mortem 
respectively. indicating presence of pulmonary artery wall thickening. Interestingly, similar ranges of 
increase (7-10%) were observed on explanted lungs of COPD-affected patients, compared to controls 
(120, 149, 151). A previous histomorphometric study of Saetta et al. on human fatal asthma detected 
increased eosinophilic infiltration of pulmonary artery adventitia but failed in demonstrating 
pulmonary artery wall remodeling (141). Nevertheless, the study was performed on lungs of patients 
died after a sudden asthma attack. Sudden fatal asthma prevents a chronic progressive evolution of 
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the disease, typical of severe equine asthma and COPD, required to induce vascular remodeling. 
Furthermore, Saetta et al. assessed remodeling using a 1D morphometric parameter (artery wall 
thickness) instead of a 2D morphometric parameter (artery wall area), as in the present study. 
Remodeling affects artery wall circumference in a patchy manner, therefore isolated linear 
measurements are less accurate and reproducible than bidimensional measurements (154). 
The post mortem regional sampling showed that pulmonary artery remodeling did not involve the 
whole equine lung but affected the caudodorsal lung fields and the lung apex. It is interesting that the 
caudodorsal lung fields represent the main site of vascular remodeling also in equine EIPH (153). 
Preferential location of vascular remodeling in the caudodorsal regions depends on lung blood flow 
distribution pattern in the equine species (152). In standing horses at rest, lung blood flow distribution 
is related more to local differences in vascular resistance than to gravity, increasing in a dorsal and 
caudal direction (155). Therefore, higher perfusion of caudodorsal lungs means higher delivery and 
infiltration of inflammatory cells during acute lung inflammation. In rodent asthma models, 
remodeling of pulmonary arteries is correlated to increased eosinophilic infiltration, suggesting that 
blood-derived inflammatory cells can contribute to initiation and progression of vascular remodeling 
(142). Another factor that may contribute to regional distribution of vascular remodeling is the 
regional heterogeneity in mechanical properties and vasoreactivity of small pulmonary arteries, as 
recently demonstrated in the equine lung (156, 157). Involvement of cranioventral pulmonary arteries 
(lung apex) in pulmonary vascular remodeling of the equine lung represents a recent and surprising 
finding. Although blood flow distribution is lower in the lung apex, cranioventral small pulmonary 
arteries appear more prone to remodeling as they become stiffer than in caudodorsal regions in 
response to exercise. This suggests regional differences in vessel mechanical reactions in response to 
yet unidentified stimuli (157). Similar enhanced remodeling of cranioventral pulmonary arteries may 
be evoked also in severe equine asthma, nevertheless the determining factors merit further 
investigation. Also, endothelial dysfunction may occur in severe equine asthma as in human COPD, 
resulting in impaired production of vasodilating mediators such as prostacyclin and nitric oxide (NO) 
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(117). It has been recently demonstrated that prostacyclin production contributes to pulmonary 
vasomotor tone both in cranioventral and caudodorsal equine lung, while NO role is significant only 
in the cranioventral lung (156). In human COPD, endothelial dysfunction appears to play a role in 
inducing remodeling of pulmonary arteries and similar mechanisms may be implicated also in 
regional remodeling of the equine lung (120, 151). It is important to note that pulmonary artery 
remodeling was demonstrated post mortem in the same region sampled by in vivo thoracoscopy. 
Therefore, specimens collected with this technique are representative and adequate to investigate 
prospectively in vivo vascular remodeling evolution and response to treatment. 
In the present study, in vivo wall area mean values were about 25-30% higher than those calculated 
post mortem, both in asthmatic horses (74.51 ±2.78 in vivo and 49.09 ±12.52 post mortem 
respectively) and in controls (67.26 ±6.67 in vivo and 38.31 ±5.70 post mortem). Therefore, 
independently from the group, pulmonary arteries were thicker when lung samples were collected in 
vivo. In vivo, both groups had similar negligible degree of artery collapse, with a high narrowing 
index (0.65 ±0.04 in controls and 0.70 ±0.04 in asthmatic horses). It has been shown in humans that 
minimally invasive techniques applying high traction force to harvest systemic vessels impair 
endothelium-dependent relaxation, without affecting contractile response (158). Methodological 
factors related to the cutting procedure and traction occurring during in vivo lung biopsy collection 
may have been the cause of the difference between post-mortem and in vivo measurements. 
Relaxation of pulmonary arteries could have been impaired by the sampling method, leading to a 
greater degree of collapse and lower thickness of the arterial wall in post mortem samples when 
compared to in vivo biopsies. Post mortem pulmonary arteries of asthmatic horses have a significantly 
higher narrowing index than those of controls (0.70 ±0.04 and 0.58 ±0.04 respectively). Pulmonary 
arteries showed increased tendency to collapse in controls compared to asthmatic horses at post 
mortem evaluation while degree of collapse was similar and negligible in both groups at in vivo 
evaluation. The fact that differences in degree of collapse were detected at post mortem but not in 
vivo suggests that post mortem alterations occurred differently in asthmatic and healthy horses. 
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Previous studies on experimental animal models documented that allergic lung inflammation is 
associated with hypercontractility and impaired relaxation of both pulmonary and systemic 
vasculature (159-161). Similarly, pulmonary arteries of asthmatic horses may show hypercontractility 
and impaired post mortem relaxation, compared to healthy horses. However, difference in wall area 
(expression of remodeling due to wall thickening) was not affected by methodological or reactivity 
differences between groups and was similarly detected both in vivo and post mortem, therefore 
suggesting consistent remodeling of pulmonary artery walls in asthmatic horses.  
Presence of remodeling was further supported by point-counting results on immunostained 
pulmonary arteries, showing a significant increase in the VSM of asthmatic horses. This is the first 
study showing pulmonary VSM mass remodeling in a spontaneous asthma-like disease. However, 
involvement of VSM in pulmonary artery remodeling has been already demonstrated in rodent asthma 
models and in other chronic spontaneous lung disorders, such as human COPD or equine EIPH, using 
similar immunostaining technique with α-SMA (142-144, 153, 162-164). Increase in VSM mass of 
muscular pulmonary arteries could be induced by hypoxia-exposure, because persistent HPV results 
in VSM contraction and “work” hypertrophy, as shown by studies on experimental animal models 
(165). Chronic hypoxaemia is present in severe asthmatic horses and is able to evoke HPV as well, 
and therefore could have been contributing to the VSM mass increase detected by the present study 
(50, 110). In addition to hypoxaemia, airway inflammation may also contribute to the VSM mass 
increase. In rodent models, allergic airway inflammation increased pulmonary artery smooth muscle 
cells (PASMC) turnover inducing an overall increase of VSM mass with similar time course and 
magnitude to airway smooth muscle (ASM) remodeling, both being not reversible after one month of 
antigen avoidance (142, 143). An increase in ASM mass with increased myocyte proliferation rate is 
reported also in severe asthmatic horses (7, 45). Similarly, in severe equine asthma, although lung 
function and airway inflammation significantly improved after short term antigen avoidance (disease 
remission), smooth muscle remodeling changes are not affected, both in muscular pulmonary arteries, 
as shown in the present study, and in small peripheral airway, as previously shown (7).  
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However, magnitude of ASM remodeling appears greater than VSM remodeling in the equine species 
(45). Airway smooth muscle mass was previously shown to be two-folds increased, while the VSM 
mass increase in the present study was about 13% in asthmatic horses compared to controls. As the 
PASMC turnover was not evaluated, whether the increase in VSM mass is due to PASMC 
proliferation, hyperplasia or hypertrophy is still to be investigated. Time course of VSM remodeling 
development was not examined in the present study. However, consistent differences between ASM 
and VSM remodeling magnitude suggest that the two phenomena evolve in the same time but 
showing different rapidity. Acute episodes of bronchoconstriction and allergic airway inflammation 
may initiate both ASM and VSM remodeling after short-term antigen challenge, as shownin rodent 
models. Then, rapidity of progression may differ between ASM and VSM during the evolution of the 
spontaneous disease, although influencing factors are still unidentified  (142). An hypothesis could 
be that proliferation of ASM maybe abnormally up-regulated due cellular intrinsic abnormalities 
involving asthmatic ASM cells but not PASMC (166).  
In COPD, VSM mass increases in muscular pulmonary arteries mainly because of intimal 
longitudinal muscularization, with significant intimal thickening (162). A thickening of the medial 
layer is also detected in advanced stages because of circumferential VSM hypertrophy (163). In the 
present study, an overall increase in pulmonary artery VSM with significant wall thickening was 
detected, without specific thickening of intimal and/or medial layer was remarkable. Pulmonary 
artery remodeling could be patchy, affecting irregularly intimal and/or medial layer, therefore total 
wall VSM amount could be increased without increase of VSM amount within a single layer. Absence 
of specific intimal/medial thickening could be also related to methodological limitations. Intimal and 
medial area were not systematically evaluable because a well stained internal elastic lamina was not 
always present, reducing power of the histomorphometric assessment. Remodeling itself may cause 
loss of internal elastic lamina integrity and staining definition, as occurring in equine EIPH. In this 
equine lung disorder, pulmonary arteries remodeling pattern is similar to what was found for severe 
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equine asthma in the present study, showing artery wall thickening, medial smooth muscle 
hypertrophy, intimal hyperplasia with elastic laminas inconsistence and lack of organization (153).  
In severe asthmatic horses, the increase in pulmonary artery VSM mass could contribute to PH onset 
during disease exacerbation, by enhancing magnitude of HPV. Experimentally-induced hypoxaemia 
increases mean pulmonary artery pressure (mPAP) both in normal and in asthmatic horses, however 
only asthmatic horses develop pulmonary PH (51). Furthermore, persistence of VSM mass increase 
and related artery wall thickening during remission may explain the higher mPAP values, although 
within physiological ranges, in asthmatic horses during remission than in controls (51). It is 
interesting that the present study detected a percentages of VSM mass increase in severe asthmatic 
horses in remission was about 13% when compared to controls, while an earlier report showed that 
the percentages of mPAP increase in severe asthmatic horses in remission compared to controls was 
about 16% (51). 
In the present study, pulmonary artery remodeling did not affect the amount of vascular ECM. This 
result is somewhat surprising when compared with pulmonary artery remodeling observed in other 
spontaneous human or equine chronic lung diseases. The increased in the ECM mass in pulmonary 
artery of patients with COPD is mostly affecting the intima (162). In equine EIPH, there is increased 
ECM deposition in all layer of the pulmonary artery wall (153). Nevertheless, these discordances 
between COPD, EIPH and severe equine asthma may be related to differences in the etiological 
factors involved. In humans, intimal fibrosis is detectable in smokers before COPD onset, therefore 
the endothelial damage directly due to smoke chemical stimulus represents the most likely cause 
(162). Lung hemorrhage is followed by hemosiderin accumulation and is associated with progressive 
and massive lung fibrosis, likely contributing to the increased in vascular ECM typical of equine 
EIPH (153, 167). Furthermore, results of the present study are partially concordant with previous 
studies on experimental models of asthma. In rodents, an increased collagen content due to enhanced 
pro-collagen deposition is detected during sustained exacerbation but newly deposed pro-collagen 
content in the medial layer was marginal (142, 144). Pro-collagen deposition in rodents was mainly 
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in the perivascular layer, that was not examined in the present study. Therefore, perivascular changes 
and especially ECM deposition merit to be further investigated in severe equine asthma, using specific 
collagen and procollagen immunostainings. 
The present study examined reversibility of pulmonary artery remodeling after long term asthma 
treatment. We observed that 12 months antigen avoidance strategy, known to control both airway 
obstruction and inflammation in affected horses, reversed the increase of pulmonary artery wall area 
and VSM mass. However, VSM decrease obtained in horses treated long term (12 months) with 
inhaled corticosteroids was less predictable, even if it was combined with antigen avoidance in the 
last 6 months of the study. Based on these findings, we postulated that airway inflammation may play 
an important role in the development of pulmonary artery remodeling, as VSM mass reversibility is 
achieved only with long term antigen avoidance strategy that normalizes both lung function and 
airway neutrophilic count (8). However, after long term treatment with inhaled corticosteroids, a 
significant decrease of pulmonary artery wall area was detected in association with a significantly 
higher degree of pulmonary artery collapse during histological processing (lower narrowing index). 
These results suggest a vasorelaxation in asthmatic horses following corticosteroid administration 
that is not related to airway inflammation modulation. Although this remains to be confirmed, both 
in vitro and experimental in vivo studies have shown that corticosteroids may counteract oxidative 
stress in asthma and improve the relaxation response of pulmonary arteries by decreasing oxidative 
stress, up-regulating expression of NO synthases and increasing bioavailability of NO in pulmonary 
endothelial cells (168, 169).  
In conclusion, results of the present study indicate that there is a remodeling of pulmonary arteries in 
severe equine asthma independently from the disease status (exacerbation or remission) determining 
artery wall thickening and involving an increase of VSM mass. It was possible to study prospectively 
the reversibility of VSM mass increase in the same animals, which was achieved only with long term 
antigen avoidance strategies, suggesting a role for inflammation in the persistence of these structural 
vascular changes. Mechanisms of VSM remodeling, and endothelium and adventitial remodeling 
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remains to be investigated as well as the involvement of distal arterioles, pulmonary capillaries and 
veins. However, presence of pulmonary artery remodeling represents a new fascinating discovery in 
spontaneous asthma-like disease. Further clinical studies may investigate the role of hypoxaemia and 
inflammation in inducing VSM remodeling as well as its impact on pulmonary artery pressure and 
cardiovascular complications of severe equine asthma. 
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